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Enhancing immune checkpoint blockade and cancer immunotherapy via tissue targeting 
and biomaterial nanoparticles 
Immune checkpoint blockade (ICB) has emerged in recent years as one of the most promising new 
cancer therapies. However, a significant majority of patients receiving these therapies 1) do not 
respond, 2) experience adverse side effects, or 3) respond initially but relapse. Overcoming these 
limitations is therefore a critical hurdle in improving these treatments. Checkpoint pathways are 
active in both the tumor microenvironment and lymphoid tissues where they prevent T cell 
cytotoxic function and activation, respectively. While improving tumor and lymphoid delivery of 
these therapies offers a promising approach to advance the efficacy of ICB, clinical applications 
of ICB have so far only relied on systemic administrations, which often result in poor tumor and 
lymphoid accumulation. Additionally, administration of combination immunotherapies outside of 
ICB is challenging as many of these drugs are short-lived in vivo, are insoluble in aqueous 
solvents, and are not targeted to the cells of interest leading to off-target side effects. Given the 
current state of ICB therapy, the focus of this thesis work is to address the drug delivery barriers 
associated with conventional systemic administrations and non-targeted delivery of immune 
modulators.  This work explored two unique delivery strategies: one which proposes drugging 
tumor draining lymph nodes with ICB therapies by way of lymphatics using local rather than 
systemic administrations to enhance anti-tumor efficacy; and the second which proposes a novel 
drug-eluting ICB platform by engineering an antibody-nanoparticle conjugate system for 











Immunotherapy has emerged as the most promising new treatment approach for an array of 
advanced malignancies (1). Many of these therapies work directly on T lymphocytes, specifically 
cytotoxic CD8 T cells, by promoting proliferation and re-invigorating cytotoxic potential by 
blocking suppressive pathways (2). In particular, immune checkpoint blockade (ICB) using 
monoclonal antibodies (mAbs) such as anti-Programmed Death 1 (aPD1) and anti-Cytotoxic 
Lymphocyte Associated Protein 4 (aCTLA) are increasingly utilized as cancer immunotherapeutic 
agents due to their capacity to specifically recognize cell surface markers on immune cells and 
modulate their signaling effects to enhance anti-tumor adaptive immunity. Furthermore, many 
other immune pathways have been identified and targeted for drug modulation using traditional 
small molecule drugs by way of inhibitors or antagonists including the transforming growth factor 
beta (TGFb) and adenosine pathways (3, 4). The use of these cancer immunotherapies and others 
has generated unprecedented improvements in survival including complete, durable responses 
unseen with chemotherapies.  
Although many immunotherapies generate robust and durable responses, a majority of 
patients do not respond to such treatments or respond initially but experience relapse after initial 
response (5, 6). Moreover, treatment associated toxicities are prevalent due to systemic 
accumulation of therapies leading many patients to stop these therapies (7). Thus, there is an urgent 
need to better elucidate these therapies and look for ways to improve their efficacy while reducing 
side effects. Due to the integral role T lymphocytes have in robust anti-tumor immune responses, 





body including lymphoid tissues, where they are primed and activated, and the tumor 
microenvironment (TME), where they carry out their effector function by way of tumor killing. 
Modifying administration route represents an interesting approach to modulate mAb 
pharmacokinetics due to their large and thus unique biodistribution following cutaneous injections. 
Furthermore, combination of multiple immunotherapies has emerged in recent years as a 
promising approach to improve efficacy as inhibition of multiple, non-redundant pathways can 
augment T cell function and prevent secondary relapse. Hence, formulation changes to improve 
codelivery of mAb and small molecule therapies to the same cell of interest in order to concurrently 
modulate multiple pathways are of high interest. Despite different administration routes being 
recently explored for ICB therapies to improve patient compliance (8), the effects on mechanism 
of action have not been explored. Furthermore, advances in drug formulations have primarily been 
focused on instant release strategies, rather than sustained drug release. 
The overall goal of this work is to investigate the effects of drugging immune checkpoint 
pathways in tissues where they are active, including the TME and lymphoid tissues while rationally 
designing a biomaterial platform capable of delivering multiple immunotherapies to cells of 
interest. We addressed this by utilizing four different administration routes to enable drugging of 
the TME, spleen, tumor draining lymph nodes (TdLNs), and non-tumor draining lymph nodes 
(nTdLNs) and monitored the effects on the anti-tumor response and toxicity. In order to drug T 
cells with multiple therapies simultaneously, we developed an antibody-nanoparticle conjugate 
(ANC) platform designed to 1) harness the conjugated antibody as both a targeting protein and 
therapeutic and 2) release small molecule immunotherapies over a prolonged period of time. By 
employing these two approaches, we demonstrate improved anti-tumor immune responses by way 
of both efficacy and toxicity which presumably results from enhanced delivery of 






1.2       Specific Aims 
1.2.1 Specific Aim 1: Evaluate the effects of ICB in the TME and TdLNs by different 
administration routes in multiple mouse tumor models.  
My working hypothesis is that ICB therapies can be improved by enhancing the delivery 
of these drugs to the tissues of interest, specifically where these pathways are active, i.e. the TME 
and TdLN as tumor associated antigen is present in the LNs thereby enabling the activation of 
tumor specific T lymphocytes. To explore this idea, this aim will focus on different administration 
schemes including; 1) intraperiterional (i.p.) – current standard in mouse models comparable to 
intravenous (i.v.) administration done in the clinic that results in systemic mAb distribution with 
minimal accumulation in the TME and lymphoid tissues, 2) intratumoral (i.t.) – results in high 
mAb delivery to both the TME and TdLN, 3) ipsilateral forearm (i.l.) – results in high delivery to 
the TdLN, and 4) contralateral forearm (c.l.) – results in high delivery to a nTdLN. Through the 
use of in vivo mouse tumor models (melanoma and breast cancers), we were able to assess the 
biodistribution of mAbs following different routes of administration and subsequently investigate 
the effects on the anti-tumor immune response, specifically the efficacy and immune related 
adverse events (iRAE). We demonstrate that following cutaneous administration routes (i.e. i.t., 
i.l., and c.l.), we achieve high mAb concentrations in draining lymph nodes (dLNs), specifically 
the TdLNs following i.t. and i.l. administrations and the nTdLNs following c.l. administration. 
Furthermore, mAb that accumulates in dLNs has access to the deeper areas of LNs where T cells 
reside. Similar levels of mAb accumulate in the spleen while only using an i.t. administration 
results in appreciable tumor concentrations of mAb allowing for careful investigation into 
drugging different tissues. In vivo, we show i.l. administration improves anti-tumor responses 





comparable efficacy to drugging both the TdLN and TME suggesting the TdLN has a  prominent 
role in mediating ICB efficacy. To extend our findings, we performed dose titration studies to 
explore whether lower doses could maintain efficacy, while reducing off-target tissue mAb 
accumulation and toxicities, a major barrier in ICB therapies. We found i.l. and i.t. administrations 
could reduce dosing by an order of magnitude while concomitantly reducing mAb accumulation 
in systemic tissues. These results suggest the importance of TdLNs for generating robust anti-
tumor immune responses and that simply modifying the route of administration allows for efficient 
targeting of these tissues.  
1.2.2 Specific Aim 2: Engineer an ANC platform to enable codelivery of mAb and small 
molecule drugs to augment immunotherapies.  
My working hypothesis is small molecule immune modulators are ineffective as they are not 
targeted to their cells of interest and thus can be improved by targeted and sustained delivery to T 
cells using antibody- or affinity-directed carriers to prolong interaction with T cells leading to 
improve efficacy. This can be achieved using poly(propylene sulfide) NPs as 1) the hydrophobic 
core of the NP allows for encapsulation and sustained release of small molecule drugs and 2) the 
versatile corona can be derivatized to conjugate mAbs to the surface to act as both targeting and 
therapeutic proteins. This aim first focused on synthesizing an ANC platform that retains the 
binding ability of the mAb and whether encapsulated drug molecules into the core of the NPs could 
sustain drug modulation. The second part of this aim focused on applying the ANC platform to in 
vivo mouse tumor models to improve cancer immunotherapy applications. To engineer ANCs, we 
employed a very mild synthesis scheme in order to maintain the antigen binding fragment (Fab) 
affinity which was done using a reducible disulfide chemistry in aqueous conditions. Using this 
scheme, we show control over the degree of mAb thiolation and thus can control mAbs per NPs 





ANCs can target lymphoma T cells and deliver paclitaxel, a chemotherapeutic, over a prolonged 
period of time while controlling the drug loading into the ANC thus highlighting the drug eluting 
potential of this system. These results highlight the feasibility of targeting antigen expressing cells 
along with sustained drug modulation to target cells requiring no stimuli other than time related 
diffusion. We further demonstrate the capability of this platform using combination therapy with 
ICB mAbs and encapsulated small molecule immune modulators, specifically using a (TGFb) 
inhibitor and adenosine receptor antagonist (ArA) to target non-redundant pathways. We 
demonstrate targeted (PD1 or CTLA4) ANCs afford an improved therapeutic outcome compared 
to non-targeted isotype-ANCs by way of reduced tumor burden and prolonged animal survival. 
These results highlight the versatility of this ANC platform to deliver a range of both mAbs and 
small molecule drugs to target cells as well as suggest the enhancement of immunotherapies may 
lie in the co-delivery of multiple modulators to T cells.  
1.3 Significance 
 
The work presented herein provides insight on various immunotherapies, specifically the 
mechanisms of action for two ICB mAb therapies at the tissue level and innovations in drug 
delivery strategies to co-deliver therapies to checkpoint expressing cells for improving anti-tumor 
response rates. First, this work identifies TdLNs as a therapeutic tissue of interest for ICB 
immunotherapies, an idea mentioned in the field, but scarcely explored. To this end, drugging 
TdLNs augments the efficacy and reduces toxicities; a concept that has not been thoroughly 
explored to our knowledge. Second, this work has engineered a unique drug delivery carrier 
capable of sustained delivery of small molecule therapeutics without requiring a stimulus to release 





Specific Aim 1. While much research has gone into understanding how and why checkpoint 
therapies work in some cancer patients and not in others, most of this research has primarily 
focused on exploring systemic effects from the blood, with emerging literature exploring the TME. 
Few studies have gone into understanding how these therapies work in the TdLN or the priming 
phase of the adaptive immune response. However, lymphoid tissues, specifically the spleen, have 
emerged in recent years as important tissues for ICB efficacy in chronic infections (9, 10). In the 
context of cancer, the TdLN may be a more appropriate tissue as it is bathed in tumor associated 
antigen and tumor specific T cells may be generated here. Furthermore, TdLNs are important in 
controlling cancer dissemination. Utilizing local, cutaneous administration routes to target the 
TdLNs allows for an order of magnitude increase in mAb exposure relative to a systemic 
administration routes (i.p./i.v.), and thus dose sparing with reduction of accumulation in systemic 
tissues that contribute to iRAEs. Utilizing a local administration also enables mAb to access 100% 
of LN-resident T cells by 24 hours after injection, a phenomenon not thought possible due to the 
size restriction barriers within the LN. This approach provides broad insight into the mechanisms 
of action for ICB in the cancer setting, specifically that ICB provides assistance in activation and 
proliferation of tumor specific lymphocytes outside of the TME and has potential for translation 
into the clinic and other ICB mAb therapies. 
Specific Aim 2. Drugging multiple signaling pathways in T cells has the ability to improve anti-
cancer immune responses as monotherapies consistently fail patients due to upregulation and 
exploitation of other pathways by cancer cells. However, many small molecule therapeutics have 
short circulation times, accumulate nonspecifically in blood rich systemic tissues leading to 
toxicity and side effects due to their pleiotropic effects, and the scarcity of tumor and blood resident 
T cells make the probability of drug interaction unlikely following administration. This has spurred 





they enable targeted delivery to the cognate ligand of the Fab sequence. However, many small 
molecule therapeutics are hydrophobic making them challenging to conjugate and keep soluble 
post conjugation to mAbs. Furthermore, chemical modifications of small molecule drugs can 
diminish drug activity by changing the drug structure and binding to target proteins. Amphiphilic 
polymer nanoparticles are alternative drug carriers that overcome the aforementioned solubility 
and circulation time barriers. However, delivery to T cells is challenging due to their lack of 
phagocytosis/pinocytosis. To overcome this barrier, we engineered an ANC that has the ability to 
target non-phagocytic T cells based off the conjugated mAb Fab specificity, and does not require 
chemical modification of the drug, but instead relies on encapsulation to retain the drug efficacy. 
Therefore, using an ANC can improve interaction of small molecule drugs with T cells while 
concurrently blocking the cognate pathways to the Fab specificity (i.e. anti-PD1 can target PD1 
expressing cells while also blocking ligand binding to PD1). Moreover, this ANC system enables 
encapsulated drug to slowly diffuse out of the NP core based off the molecular weight and logP of 
the molecule, meaning the NP does not require a stimulus (e.g. intracellular lysosomal degradation 
or enzyme presence) to release and allow drug cargo to act on target, an ideal feature when 
targeting inert cells like T lymphocytes. Furthermore, this platform allows for dramatic increases 
in drug loading; most ADCs are limited to 2-10 drugs/mAb (11) whereas this ANC can encapsulate 
~100-500 drugs/NP or mAb pending the mAbs per NPs. Therefore, a drug depot or drug eluting 
ICB platform results since drug release from the ANC is sustained and time dependent which 
allows for a wide variety of T cell immunotherapeutic applications including; teasing out the 
effects of dual targeting of independent pathways in the same cell vs multiple interventions not 






CHAPTER 2. BACKGROUND AND LITERATURE REVIEW 
 
2.1  Cancer Immunotherapy  
Cancer immunotherapy has emerged in recent years as one of the most promising new 
types of therapy and is providing a paradigm shift for cancer treatment. Unlike traditional cancer 
interventions (i.e. surgery, radiation, chemotherapy), immunotherapy works with the patient’s 
immune system through a variety of ways including reinvigoration of T cells and has immense 
potential for generating long-term responses against the primary tumor, metastatic tumors, and 
recurring tumors after initial therapy. In order for immune cells to eliminate cancer cells, a series 
of steps must be carried out, known as the cancer immunity cycle. This cycle requires; 1) tumor 
associated antigen to be released in the TME, 2) uptake of this antigen by APCs, 3) activation of 
naïve lymphocytes – generally in lymphoid tissues like the TdLN, 4) trafficking of activated 
lymphocytes from the TdLN to the TME, and 5) recognition and elimination of cancer cells by 
lymphocytes (12). When this cycle is compromised, cancer cells evade immune destruction and 
continue to grow. One way cancer cells have evolved to evade immune destruction is by harnessing 
immune checkpoint pathways, which are generally surface receptors found on both cancer and 
immune cells. Upon engagement of these proteins, immune cells are generally suppressed, either 
at the tumor killing stage or the activation stage in the case of T cell checkpoint pathways. Thus, 
therapies to block these particular inhibitory pathways have been developed to reinvigorate 
immune cells and enable an effective anti-cancer immune response, known as ICB therapy. In 
addition to ICB, many other immunotherapies have been discovered that contribute to immune 
suppression and thus cancer progression. Two rather interesting pathways that differ from immune 
checkpoints, but have interactions are the TGFb and adenosine pathways which promote immune 





This background will discuss further details on immune checkpoint pathways including 
their roles, expression, effects on the anti-cancer immune response, and ICB therapies. The TGFb 
and adenosine pathways will also be discussed further delineating their role on immune 
suppression and current therapies targeting these pathways.  
2.1.1 Checkpoint pathways and mAb inhibitor therapies 
Cytotoxic T-lymphocyte-associated protein 4. CTLA4 is a transmembrane receptor found 
on a variety of T cells including activated, memory, cytotoxic, and regulatory cells as well as B 
cells (13). In contrast to CD28, a stimulatory co-receptor, CTLA4 acts as an inhibitor of T cell 
activation promoting an anergic phenotype similar to TCR stimulation alone (Fig. 1) (14). 
Although counterproductive to cancer therapy, CTLA4 is vital for homeostasis as deletion of Ctla4 
in mice leads to a fatal, rapidly progressive lymphoproliferative disease causing death by 3-4 
weeks of age in mice suggesting a role in lymphoid tissues (15). The expression of CTLA4 is 
induced following TCR stimulation and is thus rarely found on resting T cells, in fact CTLA4 
expression is enhanced by CD28 costimulation (16). Following TCR engagement, CTLA4 is 
trafficked from intracellular vesicles to the cell surface (17, 18). Maximum protein expression of 
CTLA4 is around 24-48 hours post-TCR stimulation and decreases thereafter, however antigen 
experienced memory CD4 and CD8 T cells as well as regulatory T cells (Tregs) constitutively 
express CTLA4 (19). While CD4h, CD8, and Tregs all express CTLA4, it appears to be most 
important on Tregs as it promotes their suppressive function and is constitutively expressed at high 
levels (20). One of the main ways CTLA4 inhibits T cell function is by out-competing CD28 for 
the B7 ligands found on APCs leading to inadequate T cell stimulation (21). CTLA4 has a higher 
affinity and avidity for B7 ligands allowing it to exert inhibitory functions at lower expression 
levels compared to CD28 which is critical as this generates a threshold for activation to limit low-





CTLA4 expressing cells have been shown to acquire B7 ligands from APCs by a trans-endocytosis 
process leading to degradation of B7 ligands in lysosomes of T cells (22). This process leads to 
lower B7 ligand expression and availability on APC surfaces providing another explanation for 
the suppressive effects of CTLA4.  
 
Programmed Death-1 & Programmed Death-Ligand-1/2. Similar to CTLA4, PD1 is an 
inhibitory transmembrane receptor found primarily on activated T cells with minimal expression 
Figure 1: Immune checkpoints are active within tumors and secondary lymphoid tissues. 
Figure 1: Immune checkpoints are active within tumors and secondary lymphoid tissues. 
Top: In the TME, effector T cells primarily express PD1 and become exhausted upon chronic 
engagement with PDL1 by tumor cells. Tumor resident Tregs express PD1 and CTLA4 and upon 
engagement with cognate ligands may secrete suppressive cytokines (e.g. TGFb ) leading to 
tumor progression. Bottom: In LNs, T cells undergoing activation by APCs rapidly express both 
PD1 and CTLA4 post TCR engagement dampening T cell activation via exhaustion or anergy 





























on resting immune cells restrained primarily to activated cells including T, B, NK, NKT cells, 
DCs, and macrophages (23, 24). In studies exploring the role of PD1, knockout PD1 mice leads to 
a delayed-onset tissue specific autoimmune disease after 6 months of age suggesting the role for 
PD1 to be at peripheral tissues (25). Further studies of PD1 have been in the context of chronic 
infections where blockade of the PD1 pathway restores T cell function and thus helps protect the 
host from tissue destruction in a chronic antigen stimulation setting (26). Furthermore, it has been 
shown PD1 is highly expressed on dysfunctional T cells during chronic infections, but not 
expressed on resting memory T cells in an acute infection (27). PD1 has two known ligands, PD-
ligand 1 (PD-L1) and PD-ligand 2 (PD-L2) where PD-L1 is broadly constitutively expressed on 
hem atopoietic cells (T, B, DCs, and macrophages) and nonhematopoietic cells (endothelial and 
epithelial cells) whereas PD-L2 has a more restricted expression found on DCs, macrophages, and 
mast cells (Fig. 2) (24, 28). Both ligands are inducible by inflammatory signals including type I 
and II IFNs and TNF-alphas for PD-L1 and IFN-gamma, GM-CSF, and IL-4 for PD-L2 
highlighting the importance of this pathway in regulating effector T cell responses in both 
peripheral and lymphoid tissues (28). In addition to inhibiting effector T cells, PD1 plays an 
important role development, maintenance, and function of Tregs. PD-L1 on APCs has been shown 
to induce Treg differentiation and helps to maintain their suppressive capabilities (29). 
Clinical checkpoint inhibitor therapies. As these pathways emerge and become better 
understood, drug development has explored ways to block these inhibitory pathways and restore 
effector function and inhibit regulatory T cells for cancer immunotherapy. This has primarily been 
through the use of mAbs that are nonstimulatory and bind to different epitopes than endogenous 
ligands leading to blocked interactions.  
Anti-CTLA4 in Cancer. Due to the widespread expression of the inhibitory receptor, 





tumor models, it demonstrates delayed tumor growth and rejection of implanted tumors (30). 
Moreover, aCTLA4 can promote immune memory leading to subsequent rejection of a second 
tumor without any additional anti-CTLA4 (31). In less immunogenic tumors, combination of 
aCTLA4 with another agent is usually required including radiation, chemotherapy, or a cancer 
vaccine – these all suggest that any method of providing a tumor associated antigen in combination 
with aCTLA4 will lead to synergy by rejecting T cell tolerance to these antigens leading to 
enhanced anti-tumor efficacy (32–35). On a mechanistic level, aCTLA4 can mediate its effect on 
both the regulatory and effector T cell compartments (36). Numerous studies have shown aCTLA4 
when injected in the TME leads to the elimination of tumor resident Tregs by an analogous method 
to antibody dependent cellular cytotoxicity where aCTLA4 will coat constitutively CTLA4 
expressing Tregs and tumor resident macrophages will subsequently eliminate these decorated 
Tregs (37–39). This is due to the Fc region of the aCTLA4 clone used as some clones will bind to 
Fc gamma receptors found on macrophages whereas some will not. However, studies have shown 
isolated blockade on the Treg or effector cell compartment does not lead to anti-tumor efficacy 
and concurrent blockade of both compartments is necessary (36). As previously mentioned, 
CTLA4 has roles in preventing activation of lower affinity TCRs, however the use of aCTLA4 has 
been shown to broaden the tumor specific CD8 T cell repertoire while not affecting the numbers 
of pre-existing tumor specific T cells prior to therapy (40). This data suggests a role for aCTLA4 
not only in the TME, but also in lymphoid tissues where CTLA4 expressing CD8 T cells are 
prevented from activation until CTLA4 blockade occurs. 
Anti-PD1 and Anti-PDL1 mechanism. From early studies in chronic infections, especially 
viral infections, the PD1:PD-L1 pathway become an exciting target in cancers (41). PD1 is 
expressed by many tumor-infiltrating lymphocytes (TILs) and PD-L1 by numerous cancers and 





explored blocking this pathway in hopes to restore reinvigorating exhausted T cells (44–46). PD1 
blockade has been shown to enhance T cell cytokine production thereby restoring some of the 
cytotoxic capabilities which may lead to anti-tumor efficacy (47). Interestingly, it has also been 
shown that the PD-1 pathway also has a role during the naïve-to-effector activation and 
differentiation in lymphoid tissues motivating the modulation of this pathway here (48). 
Furthermore, literature has shown PD1 blockade acts on an exhausted stem cell like CD8 T cell in 
lymphoid tissues that promotes proliferation of these cells leading to effector like CD8 cells and 
reductions in viral loads (9, 49). Similar to aCTLA4 mAbs, the specific clone of aPD1 and aPDL1 
mAbs appears to have an effect in anti-tumor efficacy. Based on the Fc region of the IgG clone 
used, differential affinities for Fcg receptors can enhance or diminish the response thereby 
warranting careful consideration of the clone used in therapeutic experiments (50, 51). These 
literatures suggest a role of PD1 blockade in both the TME (effector phase) and also the lymphoid 
tissues (priming phase) motivating the hypothesis of enhanced delivery to the TME and TdLN. 
Dosing effects on ICB efficacy and toxicity. The dosage of mAb administered is an important 
criterion that can greatly affect therapeutic response. Accordingly, clinical studies have established 
a dose-toxicity relationship for anti-CTLA-4 therapy indicating that higher doses lead to better 
response rates but with concurrent increases in iRAE. In a study with patients with advanced 
melanoma, anti-CTLA-4 mAb ipilimumab was administered at doses of 0.3, 3, or 10 mg/kg with 
the highest tested dose resulting in better overall response rates as well as higher total lymphocyte 
counts, a measurement used as a biomarker for anti-CTLA-4 therapy efficacy/pharmacodynamics 
(52). In that same study, as the dose was increased, blood serum concentration of ipilimumab and 
iRAE also increased in a linear fashion, however at all three doses, manageable safety profiles 
were achieved (52). From a mechanistic standpoint, it has been shown in both preclinical and 





effector T cells, however, at lower doses in patients, regulatory T cells appear to be more sensitive 
to anti-CTLA4 treatment and therefore higher doses may be needed to affect effector T cells to 
result in anti-tumor immunity (53, 54). 
In contrast to CTLA-4, there are conflicting reports on the dose effects on the clinical efficacy 
and toxicity of PD-1 blockade. In patients with prostate, lung, and advanced melanoma, doses of 
anti-PD-1 nivolumab up to 10 mg/kg were well tolerated with no signs or indications of a dose-
efficacy or dose-toxicity relationship (55, 56). However, in another trial in patients with advanced 
melanoma, a dose of 10 mg/kg anti-PD-1 mAb lambrolizumab every two weeks resulted in a 
superior rate of response (52%) compared to those achieved by lower doses (2 mg/kg every three 
weeks) or the same dose, just on a less frequent schedule (10 mg/kg every three weeks) (25% and 
27% respectively) (57). However, these dose-related improvements in response rates were 
accompanied by higher frequencies of iRAE, 23% for the group receiving 10 mg/kg every two 
weeks compared to 4% and 9% for the groups receiving 10 mg/kg every 3 weeks and 2 mg/kg 
every three weeks, respectively (57). Similarly, in a preclinical study using the B16F10 melanoma 
model, improvements in tumor reduction were seen with increasing dose of mAb blocking PD-1 
(58).  
In contrast to checkpoint blockade with anti-CTLA-4 mAb and the conflicting reports on 
checkpoint blockade with anti-PD-1 mAb, the rate of patient response and frequency of iRAE with 
anti-PD-L1 treatment appears to be relatively dose independent. In a study involving patients with 
various advanced cancer types, clinical activity was seen with a dose as low as 1 mg/kg, although 
there appeared to be an improvement in response at higher doses, albeit not to a statistically 
significant level (59). However, like anti-PD-1 mAb, preclinical studies have indicated a slight 
improvement in survival and tumor suppression with increasing anti-PD-L1 mAb dose (58, 60), 





Other consistent themes seen in clinical testing are the dose-dependent blood pharmacokinetics 
and dose-independent blood pharmacodynamics or blood lymphocyte PD-1 or PD-L1 occupancy 
rates (55, 57, 59). Specifically, as the dose of administered mAb increases, serum mAb 
concentration also increases in a direct manner. However, PD-1/PD-L1 expressing blood 
lymphocytes appear to be saturated at the lowest of tested dose (0.3 mgs/kg) suggesting that as the 
dose of mAb is increased and the serum concentration increases, unwanted accumulation in off-
target tissues may result, leading to higher likelihoods of iRAE.  
With these monotherapy studies in mind, the potential for combination therapy with anti-
CTLA-4 and anti-PD-1 mAb drugs to achieve improved effects using lower doses compared to 
monotherapy was evaluated. In a study in patients with advanced melanoma, escalating doses of 
both nivolumab and ipilimumab were concurrently administered (61). Doses at or above 3 mg/kg 
of nivolumab and 3 mg/kg of ipilimumab surpassed the maximum tolerated dose (61). However, 
when reduced to 1 mg/kg nivolumab and 3 mg/kg ipilimumab, iRAE were reduced to acceptable 
levels while still achieving substantial rates of favorable responses (53%) (61). In fact, all nine of 
the patients who responded to combination therapy exhibited tumor regression of 80% or more 
compared to less than 3% of patients who received nivolumab or ipilimumab monotherapy at a 
dose of 3 mg/kg (61). These phase I results suggest that combination therapy with nivolumab and 
ipilimumab can achieve high rates of patient response while maintaining manageable safety 
profiles depending on dose.  
2.1.2 TGFb and adenosine inhibition for cancer immunotherapy 
While ICB has advanced cancer medicine tremendously in recent years, targeting 
additional pathways to treat additional cancer and improve response rates may be necessary as 





have been recently identified as active pathways in clinical and preclinical cancers providing 
potential pathways to modulate in combination with ICB. 
TGFb in Cancer. Transforming Growth Factor-b (TGFb) is a pleiotropic cytokine that can 
act as a potent growth inhibitor shown to be overproduced in a variety of cancers. TGFb is 
produced by a variety of cells including epithelial, endothelial, fibroblast, and various immune 
cells including macrophages (62). It is critical in maintaining tissue homeostasis, and prevents 
early stage tumors from progressing to malignant tumors by limiting proliferation and survival 
while also regulating the TME (angiogenesis, ECM growth, etc.) (63). However, as cancer cells 
mutate and evolve over their lifespan, they begin to become immune to the suppressive effects of 
TGFb and begin to utilize it in malignant progression and metastasis (64). For these reasons, TGFb 
inhibition has not been considered a universal approach for cancer immunotherapy as dosing and 
scheduling must carefully be considered. As tumors progress, it is thought they utilize TGFb 
through three broad ways 1) epithelial to mesenchymal transition, 2) tumor proliferation by 
affecting stromal fibroblasts, angiogenesis, and the ECM, and 3) dampening the immune 
surveillance ability (3). One way the immune system is limited is by TGFb signaling on type 1 
differentiated neutrophils, macrophages, and T cells that stimulates the release of pro-tumorigenic 
cytokines including IL-17 and more TGFb (65, 66). In addition to suppressing T cells in the tumor, 
TGFb has been shown to suppress anti-tumor immune responses in TdLNs where it can inhibit 
proliferation and function of DCs and T cells while increasing Treg accumulation leading to 
metastasis to the LNs (67, 68). 
Adenosine in Cancer. Adenosine signaling is a key signaling molecule involved in a variety 
of metabolic pathways including immunosuppression. ATP and adenosine are present at very low 
extracellular levels during homeostasis, however during inflammation and cancer, ATP is released 





is released leading to higher extracellular levels and acts as a Danger-Associated Molecular Pattern 
(DAMP) that trigger both innate and adaptive immune responses (70). However in cancer, ATP is 
constantly dephosphorylated by ectonucleotidases, primarily CD39 and CD73, leading to the 
formation of adenosine (71). In contrast to ATP, extracellular adenosine acts as an 
immunosuppressant on effector cells while promoting regulatory cell function (72). Both CD39 
and CD73 are found on a variety cells in cancer including tumor, stromal, endothelial, and 
infiltrating immune cells (71). Adenosine acts on several known G-protein-coupled receptors 
including A2a and A2b which are upregulated following immune cell activation, however  A2a 
has much higher affinity that A2b (73). Following adenosine binding to A2a, which is found on 
monocytes, DCs, T, and NK cells, intracellular cAMP is produced leading to a variety of effects 
on these cells (74). This includes reduction of cytokine production and costimulatory molecules in 
CD4 cells along with reduced proliferation and cytotoxicity in effector CD8 cells while also 
increasing Treg survival (75, 76). Furthermore, it should be noted that A2a signaling can trigger 
the expression of immune checkpoints including CTLA4 and PD1 (71). However, adenosine is 
also involved in a variety of other homeostatic metabolic pathways, therefore selective targeting 
of adenosine to specific cell subtypes is a crucial aspect of successful is desirable for cancer 
immunotherapy.   
TGFb inhibition and ICB in Cancer. Based off the wide range of pro-tumorigenic effects 
of TGFb, there are many therapeutic targets to reverse these effects including ligand traps, small 
molecule receptor kinase inhibitors, peptide aptamers, and antisense oligonucleotides (3). This 
work focused primarily on small molecule receptor kinase inhibitors to inhibit the activity of 
soluble TGFb and its downstream suppressive functions. Since small molecule inhibitors directly 
block receptor signaling compared to ligand traps and oligonucleotides, they have a distinct 





challenging to study in vivo. Nevertheless, several studies have explored the combinatorial effects 
of TGFb blockade and ICB due to TGFb strong suppressive activities against effector immune 
cells and demonstrated superior effects to either therapy alone (77–79). As previously mentioned, 
TGFb plays a role in immunosuppression in dLNs, therefore this dual blockade may be improved 
by targeting the TdLN (67). 
Adenosine antagonists and ICB in Cancer. Adenosine blockade through A2AR has been 
reported as a promising strategy for cancer immunotherapy applications (80). There are currently 
4 agents in clinical Phase 1 trials targeting the A2a receptor for cancer immunotherapy (4). These 
agents work by outcompeting endogenous adenosine to the A2a receptor and thereby can negate 
the pro-tumorigenic effects. A variety of studies have explored the effects and potential synergies 
of combining A2a blockade and ICB due to the non-redundant pathways (81, 82). Adenosine has 
been shown to increase PD1 expression, but not CTLA4 expression on CD8 TILS(82), while PD1 
blockade has been shown to increase A2A receptor expression on CD8 TILs (81). Moreover, dual 
blockade of A2a and PD1 increase IFNg and Granzyme B expression leading to improved anti-
tumor efficacy (81). These results suggest that targeted delivery of adenosine antagonists to PD1 
expressing cells can augment cancer immunotherapy.  
 
2.2 Considerations and strategies for drug delivery in cancer immunotherapy 
2.1.1 Introduction 
 Drug efficacy is in part due to drug reaching its target site of interest at the bioactive dose 
where it can then mediate its effect. In the context of the aforementioned immunotherapies, the 
desired tissues include the TME and the lymph nodes. Furthermore, T cells are a specific cell of 
interest as many drugs administered directly act on extra- and intra-cellular receptors. Thus, 





interest for improving therapy. This background will discuss the relevant concepts and barriers 
related to drug delivery to the TME and lymph node, specifically the physiologies of both tissues 
and how that dictates drug access, administration routes related to mAb pharmacokinetics and 
biodistributions, formulations that have advanced targeting of drugs and improved outcomes of 
therapeutic interventions, and the challenges associated with these immunotherapies.   
2.1.2 Limitations of immunotherapies.  
mAb drugs. Currently, ICB therapy is administered systemically through i.v. and i.p. routes 
in the clinical and preclinical setting respectively. As a result, transport of mAb to target tissues is 
based primarily on convective transport in the blood followed by diffusion and transcytosis 
through vascular epithelial cells out of the blood and into the target tissues (83). The enhanced 
permeability and retention effect (EPR) suggests mAbs should accumulate in tumors. However, 
the EPR effect has been questioned and combined with the large size of Abs, ~150 kDa, diffusion 
is limited, especially considering the density of cells and ECM in the TME, discussed further below 
(84). Combined with the selective permeation of the high endothelial venules in LNs, very little of 
mAb therapies accumulate in the TME and TdLN (85). Once mAb arrives in the TME, it is often 
restricted to the peri-vascular space due to its large size, and also its deposition to cells expressing 
its target and thus occupies only a small volume of the tumor (84). Most administered mAb instead 
accumulates in blood rich systemic organs where it is degraded following either non-specific 
pinocytosis or target-mediated drug disposition facilitated either by the constant fragment (Fc) or 
antigen binding fragment (Fab) (86). However, the circulation times of mAbs are very long, on the 
order of weeks due to Fc neonatal receptor (FcRn), a receptor important in protecting Abs from 
lysosomal degradation by binding to the Fc region in early endosomes and recycling them back 
into the extracellular space (87). As a result, this increases the chance of target tissue accumulation, 





Small molecule drugs. Unlike mAb therapies, most small molecule drugs are limited by 
short circulation times and are rapidly filtered and excreted by the kidney or catabolized in the 
liver. Most small molecules are administered orally as they are stable toward gastrointestinal 
protease activity and are permeable to intestinal linings. Following this administration, a fraction 
of the drug will enter the circulatory system where most drug is cleared in <24 hours thereby 
leading to low tumor accumulation (generally <1%) while even a smaller amount will accumulate 
in LNs (88). As a result, therapeutic efficacy is low and multiple dosing is required to reach the 
therapeutic threshold leading to toxicities associated with small molecule therapies. Small 
molecule drugs can also be injected in the peripheral skin, however due to their small size and 
permeability, they are cleared quickly from the injection site almost exclusively by the blood 
vasculature into the circulatory system (89). Thus, formulations to improve small circulation time 
and/or bias their clearance into lymphatics are required.   
Monotherapies. Although ICB has exhibited great promise for advancing cancer therapy, 
most patients receiving these therapies do not respond (~70%) and one-third of patients that do 
respond initially experience relapse. These data suggest that multiple non-redundant pathways are 
activated during therapy and thus warrant further understanding of checkpoint blockade 
mechanisms for novel combinatorial drug approaches. For example, CTLA4 monotherapy has not 
resulted in significantly enhanced response rates in various cancer types and may in part be 
explained due to increased PD-L1 expression. Therefore, the combination of aCTLA4 and aPD1 
has been widely explored leading to improved therapeutic efficacy compared to either 
monotherapy. However, this dual therapy is still ineffective in some patients warranting  
exploration into other combination with other immune modulators targeting TGFb, adenosine, and 





2.1.3 Tissue physiology and effects on drug transport 
LN physiology. A significant fraction of the total immune cells in the body are located in 
several hundred lymph nodes, in which lymphocyte accumulation, activation and proliferation are 
organized. Therefore, targeting lymph nodes provides the possibility to directly deliver drugs to 
lymphocytes and lymph node-resident cells and thus to modify the adaptive immune response. 
However, owing to the structure and anatomy of lymph nodes, as well as the distinct localization 
and migration of the different cell types within the lymph node, it is difficult to access specific cell 













Figure 2: Lymph node structure and physiology. 
Figure 2: Lymph node structure and physiology. A cross section of a lymph node is shown. 
The architecture of the lymph node can be divided into distinct areas: fluid-filled lumen structures 
(lymphatics, high endothelial venules (HEVs), capillaries and sinuses), cellular locations (B cells 
in follicles, dendritic cells and T cells in the paracortex and macrophages in the subcapsular sinus 
and medulla) and structural units (cortex, paracortex and medulla). Lymphocyte extravasation 
occurs in the HEVs. The distribution of antigens within the reticular structure is regulated by 
hemodynamic size and molecular weight by the capsule and conduit. Circulating lymphocytes 
enter through the vasculature and exit through the efferent lymphatics. Dendritic cells sample the 





The lymph node provides a specialized microenvironment to connect peripheral 
immunological information (antigens and other immune-modulatory molecules and cells) and 
circulating lymphocytes. Lymph nodes are composed of basic units called lymphoid lobules, each 
of which is drained by a single afferent lymphatic vessel sampling lymph from different drainage 
basins (Fig. 2) (90). The base of the lobule consists of slender cords that are anchored by vascular 
roots and form part of the lymph node medulla, in which the arterioles, high endothelial venules 
and paracortical sinuses reside. The apex of the lobule is separated from the surrounding lymph 
node capsule by the subcapsular sinus (91). The lobule is structurally supported by the reticular 
network, which is a fibrous sponge-like tissue composed of fibroblastic reticular cells and their 
reticular fibers. The reticular network provides a 3D scaffold for the interaction and migration of 
lymphocytes, APCs and macrophages (Fig. 2) (92). Within this mesh, conduits of the reticular 
network are formed by extracellular matrix (ECM) proteins, with a central core composed of the 
interstitial matrix molecules collagen types I and III and a surrounding basement membrane-like 
structure ensheathed by a layer of fibroblastic reticular cells (93). 
Within each lobule, B and T cells home to separate locations (Fig. 2). B cells reside in 
follicles, in which they primarily interact with follicular dendritic cells. Once activated, B cells 
proliferate and undergo clonal expansion within the follicle, which leads to the formation of 
germinal centers containing proliferating B cells and areas of displaced resting B cells, called the 
secondary follicles (94). By contrast, T cells migrate to the deeper interfollicular cortex and 
paracortex of the lobule, where they interact with migratory dendritic cells from peripheral tissues 
or lymph node-resident dendritic cells to become activated and proliferate (95). Therefore, the 
reticular network, the lobular blood vessels and the sinuses are key components of the lymph node 
providing the specific structure that enables the relatively small number of lymphocytes to 





Solutes, biomolecules and cells can enter the lymph node by afferent lymphatics, lymph 
node blood capillaries or high endothelial venules (Fig. 2), resulting in a specific distribution of 
molecules and cells within the lymph node (97). The distribution depends on the interfaces of the 
entry pathways with the other structural components and resident cells of the lymph node. 
Therefore, the specific structure and location of the different lymph node components are 
important design factors for materials targeting specific lymph node-resident cell types. Thus, 
materials need to be designed to leverage the different entry pathways to lymph nodes to enable 
targeted lymph node drug delivery: diffusive or convective delivery through the afferent 
lymphatics or capillaries, active cell-mediated migration from the peripheral tissue interstitium, 
transport in the circulating vasculature and entry through the blood capillaries and high endothelial 
venules, or direct injection. 
Tumor physiology. The TME is composed of not only malignant cells, but many other 
nonmalignant cells including immune cells, as well as proteins and vasculature (98). Since many 
cancer types express proteins of interest for immune modulation (e.g. PDL1) and lymphocytes 
reside in the TME prior to therapy, the TME represents a potential tissue target for 
immunotherapies. Tumor tissue differs greatly from healthy tissues in many physiological aspects 
(in addition to genetic abnormalities) including blood vessel development and architecture, 
lymphatic function, and extracellular matrix composition which is interest for drug delivery 
considerations (99). During tumor progression, cancer cells rapidly proliferate and thus require 
constant nutrient and oxygen supply thus promoting rapid formation of blood vessel networks. 
However, blood vessel growth and distribution in tumors is very tortuous and heterogenous which 
gives rise to hypoxic areas within the tissue due to 1) lack of oxygen and nutrient delivery and/or 
2) blood vessel collapse due to pressure from proliferating cancer cells resulting in necrotic areas 





characteristic which allows for improved macromolecule entry or exit. The lymphatics within 
tumors may be greatly impaired which can affect drug distribution. In healthy tissue, lymphatics 
play a vital role in regulating interstitial fluid pressure (IFP) by regulating osmotic balance and 
clearing larger molecules from the extracellular space. However, when lymphatics function 
improperly, as is the case in many tumors, fluid pressure builds up leading to retention of 
macromolecules and solutes in the extracellular space of tumors. Between the increased leakiness 
of tumor blood vessels and improper drainage function of lymphatics this contributes to the 
aforementioned EPR effect (101). The EPR effect is primarily related to larger compounds (<40 
kDa) which has motivated the development of many nano-formulations to improve small molecule 
delivery to tumors. However, as a result of impaired lymphatic function leading to increased IFP, 
reduced macromolecule extravasation may occur counteracting the leaky vasculature advantage. 
With constant cancer cell proliferation, the tumor environment is composed of densely packed 
cells which reduces diffusivity of macromolecules. Furthermore, the increased cell density leads 
to increased production of extracellular matrix (ECM) macromolecules including proteins (e.g. 
collagen) and polysaccharides (e.g. hyaluronan) providing further physical resistance to drug 
transport by way of diffusion (98). Taken together, these hallmarks of cancer pose serious 
challenges for efficient for drug delivery vehicles and drug distribution within tumors.   
2.1.4 Entry routes for drugging LN and TME resident T cells 
Drug entry into the LNs and TME range from passive transport via lymphatics and the 
blood vasculature to active targeting utilizing affinity via mAbs to bind to tissue and cell antigens. 
Furthermore, targeting of circulating or adoptively transferred lymphocytes or APCs to backpack 
into the tissues is another approach to enable LN and TME accumulation. Modification of 
administration is also an approach including intra -LN and -tumoral injections and cutaneous 





concentrations in the tissue targets. This section will highlight these principles further including 
discussion in the transport phenomena and intrinsic barriers with each approach. 
Drugging LN resident T cells 
Lymphatic uptake. Unlike the circulatory system, which contains a central pump, the 
lymphatics operate on a local level (102). Fluid uptake and transport in the interstitium of a tissue 
are thought to be driven by expansion and compression of the initial lymphatics: expansion leads 
to percolation of interstitial fluid through the endothelial microvalves, which causes filling of the 
initial lymphatics. The lymphatics are then compressed by the surrounding tissue, triggering the 
transport of the fluid (now termed lymph) to the large collecting lymphatics (103). 
The initial lymphatics are blind-ended and composed of non-fenestrated overlapping 
endothelial cells with filaments anchoring them to the surrounding ECM, which provides 
mechanical support against the low pressure inside the initial lymphatic vessel lumen (104). Owing 
to permeability differences between the non-fenestrated vascular capillaries and the lymphatics, 
only molecules with a certain size (10–100 nm in hydrodynamic radius) can efficiently convect 
into the lymphatics, which has important ramifications on drug formulation and delivery to the 
lymphatics (105). 
In the collecting lymphatic vessels, lymph is propelled by the synchronized movement of 
lymphatic vessel compartments called lymphangions, which contain one-way valves to propel the 
lymph in a unidirectional manner (106). Once the lymph arrives at the draining lymph node 
through one of the afferent lymphatic vessels, it enters the subcapsular sinus (Fig. 2) (107). The 
lymph then spreads into the subcapsular sinus and moves through the transverse sinuses, covering 
each lobule before finally exiting into the medullary sinuses, which merge from all lobules into a 
single efferent lymphatic vessel that may filter through subsequent lymph nodes in the same chain, 





Within each lymph node, the lymph flowing over the lobules through the subcapsular sinus 
is sampled by percolating through the conduits created by the reticular structure (108). The 
reticular network restricts the access of lymph-borne material to the paracortex, which is important 
for preserving the naive state of the lymphocyte microenvironments and for controlling 
immunogenic molecules that adversely affect the immune response in the cortex, for example, 
exosomes from tumors or soluble products produced by microbial infections (Fig. 2) (109–111). 
The efficiency of this barrier depends on the size of the lymph-borne molecules with high 
molecular weight (>70 kDa) molecules being virtually excluded from conduit and cortex access 
by the subcapsular sinus thus making T cell drugging via lymphatics a challenging task. 
Conversely, lower molecular weight species are gradually excluded, with molecules <70 kDa 
having some access to the conduits (110, 111). Permeation of low molecular weight molecules 
from the conduits to the lymphocytes within the paracortex is mostly restricted. For immune 
challenges with low antigen concentration, this restriction poses a significant barrier to the 
generation of a robust adaptive immune response. However, higher antigen concentrations could 
enable direct lymphocyte access on a physiologically relevant scale. 
To be transported to lymph nodes in the afferent lymph, drug delivery systems must 
overcome barriers, such as vasculature clearance, penetration of the epithelium of the skin and 
traversing the mucosa and gut barriers. In the tissue interstitium, where afferent lymphatic access 
is maximized, transport is restricted by the gel-like ECM, which is composed of fluid, solutes, 
fibrillar proteins and proteoglycans, which inform the design parameters for size, shape and charge 
of the drug delivery system as drug delivery systems that prevent adsorption and entrapment within 






Blood Vasculature. The blood vasculature provides an alternative transport pathway to the 
lymph nodes. The infiltration of circulating lymphocytes into the lymph node is controlled by high 
endothelial venules, which are specialized tissues lined with high (full rounded shaped) cuboidal 
endothelial cells with receptors that facilitate intravascular lymphocyte transmigration through the 
endothelial layer into the reticular meshwork (Fig. 3). Therefore, owing to the fact that the blood 
capillaries perform filtration functions, materials can be designed to leverage the diffusive and 
convective transport through these vascular structures to target cells in the lymph node. 
 
Figure 3: Canonical outlook for targeting T cells. 
Figure 3: Canonical outlook for targeting T cells. Conduit-lining dendritic cells sample antigen 
for subsequent presentation to proximal T cells. Circulating T cells can be targeted for T cell-
mediated nanoparticle trafficking into the lymph node T cell zone. Lymph node blood capillaries 
that are leaky as a result of disease allow for diffusion-mediated transport to lymph node T cells. 
Microparticles and nanoparticles can be actively targeted to high endothelial venules (HEVs) using 
anti-peripheral node addressin (PNAd) antibodies, such as MECA-79, followed by diffusion of the 





T cells primarily reside in the paracortex near the blood capillaries, and thus the blood 
vasculature is an attractive potential route to target LN-resident T cells (Fig. 3), for example, by 
mimicking homeostatic T cell trafficking from the blood to the lymph node through high 
endothelial venules (Fig. 3). The entry of lymphocytes through high endothelial venules is initiated 
by the homing receptor L-selectin (CD62L), which recognizes peripheral node addressin (PNAd), 
which is expressed on high endothelial venules in lymph nodes and upregulated at sites of chronic 
inflammation. This natural homing process can be explored for drug delivery by functionalizing 
carrier formulations with the 6-sulfo-sialyl Lewis X-targeting antibody MECA-79, which binds to 
PNAd. The functionalized particles accumulate in draining lymph nodes downstream from 
rejected transplants following intravenous injection, as draining lymph nodes have higher 
expression levels of PNAd than non-draining lymph nodes owing to chronic inflammation, 
enabling selective targeting (113). Therefore, drugs can be selectively delivered to draining lymph 
nodes, where they can then be delivered to T cell populations compared with free drug or drug-
loaded microparticles without targeting ligands. 
 Circulating lymphocytes. Antigen-specific T and B cells are rare, and the vast majority of 
naive lymphocytes are circulating between lymph nodes and the lymphatics, spending less than 
half an hour in circulation before homing to a lymphoid organ, where they take a few hours or 
days to find their cognate antigen (114). Lymphocytes primarily migrate into lymph nodes along 
the entire length of HEVs, and exit through efferent lymphatics, with T and B cell trafficking being 
substantially increased during lymph node inflammation (115). Following a tightly orchestrated 
adhesion cascade, adhesive ligands and chemokines direct lymphocyte diapedesis through the 
inter-endothelial junctions of the high endothelial venules. Once inside the lymph node, T and B 
cells home to their respective areas in the paracortex and to the follicles, guided by chemokine 





Cell homing to the lymph node can be exploited to target T cells in the lymph node by 
using cells for ‘backpacking’, that is, drug- loaded nanoparticles or carriers are covalently or non- 
covalently bound to T cells and thus shuttled to lymph nodes (Fig. 3) following adoptive transfer. 
For example, this method can be used to prolong autocrine stimulation of transferred T cells, 
triggered by conjugated nanoparticles that are tethered with anti- CD45 antibodies and release IL-
15 superagonist (IL-15Sa). This approach can be applied to support the antitumor activity of 
therapeutic T cells and increase their lymph node accumulation (118). Active targeting by cell 
homing can also be used for the treatment of lymphomas in lymph nodes. For example, T cells can 
be functionalized ex vivo with nanocapsules loaded with a chemotherapeutic, which is then 
delivered to the lymphoma (119). By engineering the T cells to be resistant to the chemotherapy, 
high- payload delivery to lymph nodes can be achieved, which ultimately leads to a decrease in 
tumor growth rate compared with traditional systemic dosing.  
Intra-Lymph Node injections. Administration of drugs in peripheral tissues or 
intravenously achieves low yet sustained levels of LN delivery, mediated by convection and active 
cell-mediate trafficking. Alternatively, drugs can be directly injected into the lymph node, a 
method that has been used for over half a century to treat lymph node metastasis (120). Direct 
lymph node injection is invasive and often used only if delivery via the lymph or blood is not 
sufficient to achieve the required drug levels in the lymph nodes. Usually, the draining lymph node 
is identified by administration of lymph-draining chromogenic colloid in peripheral tissues. The 
use of intra-LN injections has been expanded in addition to treating LN metastasis to improve 
vaccine potency in several disease indications including cancer and autoimmunity (121–123). 
Drugging tumor resident T cells 
 Blood vasculature. Systemic administration by way of i.v. injections are the most common 





blood via convection and may pass through the tumor tissue, upon which it must extravasate out 
of the blood and into the tumor tissue itself where diffusion will carry drug into deeper areas of 
the tumor away from vasculature (99). In order for drug to accumulate within tumors, the systemic 
concentration gradient of drug must stay above what it is in the tumor, thus clearance rates of drugs 
are an important factor in determining drug accumulation in tumors. Drug clearance rates are 
determined by the size of the molecule (84). Generally small molecules stay in the extracellular 
space in the plasma and are cleared via the renal system or are broken down in the hepatic system. 
Conversely, mAbs are taken up intracellularly by cells via both non-specific and receptor mediated 
uptake and subsequently degraded within lysosomes. Furthermore, drug interactions with 
receptors disseminated throughout the body, specifically FcRn and Fc-gamma receptors are 
important factors in determining drug clearance rate (83).  
 Once drug extravasates into the tumor, permeability throughout the tumor is an important 
consideration. For small molecule drugs, even with the densely packed tumor, these molecules can 
diffuse relatively easy throughout (124). However, for larger molecules like mAbs and drug 
carriers, diffusion is greatly restricted, thus convection generally dominates this transport and has 
led to direct modulation of the TME to improve drug diffusion within tumors.  By normalizing the 
tumor matrix using extracellular matrix-degrading enzymes such as collagenase or extracellular 
matrix antagonists, increased diffusivity and penetration of agents within the tumor results (125–
127). Normalization of the tumor microvasculature using anti-angiogenic therapies can also reduce 
tumor interstitial hypertension and matrix remodeling, leading to improved drug entry and 
penetration (128). It should also be noted that affinity of the mAb plays a role in drug distribution 
as lower affinity mAbs have more homogenous distribution within tumors as low affinity mAbs 
dissociate from target antigens after binding and subsequently diffuse deeper into the tissues. 





concentrations. Diffusion and permeation of tumors using higher affinity mAbs is characterized 
by mAb rapidly binding to target antigen, thus mAb is rapidly depleted as it fills up available 
antigen-binding sites and only once complete saturation of initially encountered cells occurs can 
mAbs diffuse farther into the tissue. Since endocytic uptake occurs simultaneously, complete 
saturation of target antigens by mAb diffusion within tumors from blood vasculature can be hard 
to achieve and has spurred the development of intratumoral administrations (discussed below).  
 Intratumoral delivery. An alternative to systemic administration, direct injection of 
immunotherapies into the tumor is an emerging option in the clinic as immune cells expressing the 
targets of emerging drugs are present within the TME (129). This is not a new concept as 
intratumoral delivery of pathogens has been described since the late 1800s by Dr. William Coley 
and has grown with our advanced understanding of the immune system (130). Using this approach, 
a single injection in one tumor site can generate a systemic antitumor immune response and is 
capable of triggering a more potent response while causing less off-target toxicity. Using an i.t. 
injection results in a much higher drug concentration in the TME compared to a systemic infusion 
while also lowering the total dose administered reducing drug concentrations in off-target tissues. 
This strategy has been performed with various drugs in both the clinical and preclinical setting 
including; mAbs to eradicate tumor resident Tregs (131), mAbs and cytokines (interleukin-2) to 
stimulate cytotoxic T cells (132), and  toll-like receptor agonists to activate antigen presenting 
cells (133). While promising, i.t. administration has some limitations including accessible tumor 
sites and ones which are of sufficient size for injection.  
2.1.5 Drug delivery vehicles for immunotherapies 
 Many formulations have been engineered to improve drug delivery to the TME and/or LNs 
including dendrimers (134), synthetic polymer nanoparticles (135), lipid-based drug delivery 





Formulation changes are engineered with drug entry mechanisms in mind (mentioned above) 
including passive transport via vasculature, but also allow for active targeting, enhanced retention 
at injection sites, and sustained or bolus drug release platforms. These systems work in a variety 
of ways including increasing the size of their cargo to reduce excretion rates/increase circulation 
time, modulate biodistribution, and improve solubility of hydrophobic drugs (139) and have 
improved delivery of various therapeutics including chemotherapeutics, oligonucleotides, and 
peptides (140). 
Poly(propylene sulfide) NPs. One particular formulation to achieve improved drug 
delivery is via micelles composed of block copolymers that self-assemble to various sizes in the 
nano-range (10-300 nm). Micelles composed of block copolymers including poly(propylene 
sulfide) have key features that make them attractive for delivering mAbs and small molecules to 
specific tissues. Due to self-assembly, the size of the NPs can be controlled based off polymer 
ratios allowing for NPs in the 30-300 nm size range (141). Furthermore, the hydrophobic core is a 
suitable environment for encapsulation of hydrophobic molecules and peptides which allows the 
drug to; 1) do not need to be chemically modified, a common requirement for other ADCs, 2) can 
be encapsulated at very high levels <90%, and 3) dramatically increase the solubility and alleviate 
the need to administer these drugs in organic solvents. For example, Thomas et al explored the 
ability to encapsulate paclitaxel (PTX) into the hydrophobic core of these NPs (142). PXL was 
loaded into the NPs with over 95% efficiency and released approximately 50% of PXL over the 
first 50 hours post encapsulation while maintaining the size and stability of the NPs. Furthermore, 
the encapsulated and released PXL retained its immune stimulatory activity comparable to that of 
the free PXL drug. The corona of these NPs is composed of a carboxy terminus that is 1) anti-
fouling, ideal for preventing protein deposition in vivo, and 2) the carboxy terminus allows for 





reduction-sensitive disulfide bond which can be displaced by thiol containing compounds. Van der 
Vlies et al explored the ability to derivatize PDS-NPs with several different thiolated compounds 
including a thiol containing- biotin, peptide, and ovalbumin protein (143). Using this synthesis 
approach allowed for mild reaction conditions keeping the conjugated compound intact and has 
the ability to be applied to many thiol-containing proteins. These features highlight the potential 
of poly(propylene sulfide) NPs for improving the co-delivery of small molecules and mAbs to the 
same target cell.  
While this NP system provides ideal characteristics for both encapsulation of small 
molecule drugs and surface derivatization with mAbs thereby allowing codelivery to the same 
target cell, the ability to interact with T lymphocytes remains a challenge due to their lack of 
pinocytosis. For example, Kourtis et al explored the ability to drug different immune cell 
compartments in vivo using this NP system by fluorescently labeling the NPs and monitoring their 
cellular access and uptake (144). While monocytes and granulocytes displayed distinct population 
shifts following NP uptake, B and T lymphocytes exhibited minimal shifts in NP fluorescence over 
time in vivo suggesting little uptake in these compartments. This was explored further in vitro with 
cultured splenocytes and biotinylated NPs to address whether NPs were located extracellularly or 
intracellularly on various compartments. While monocytic compartments displayed both external 
and internal NP signals via a micropinocytosis method, B and T cells had only extracellular 
staining associated with interaction with the plasma membrane. Furthermore, the level of surface 
interaction of NPs with T cells was below 1 and 5 % for CD8 and CD4 T cells respectively.  These 
results highlight the challenge in targeting T cells in vivo as they perform minor levels of 
pinocytosis and phagocytosis. 
T cell and ICB targeting platforms. Drug delivery systems that do target T cells efficiently 





to T cell surface proteins both ex vivo and in vivo. For example, Tang et al developed a thiol 
sensitive degradable protein carrier composed of therapeutic cytokines that was functionalized 
with surface anti-CD45 (145). Using this system, they were able to incubate the carrier with CD8 
T cells ex vivo and adoptively transfer in vivo where the carrier slowly degraded as T cells became 
activated and increased their surface thiol content thereby degrading and releasing the cytokines. 
Similarly, Zheng et al engineered a antibody-liposomal carrier by covalently linking the Fab to the 
surface of liposomes using an irreversible maleimide crosslinker (146). Following 
lymphodepletion in vivo, they adoptively transferred this drug carrier and showed effective binding 
to T cells in vivo demonstrating the ability to target the cells of interest. Platforms to more 
selectively target T cells of interest have also recently been developed. For example, Schmid et al 
developed a NP composed of poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG) 
which was functionalized with the Fabs of aPD1 to target PD1 expressing T cells (147). In vivo 
studies demonstrated these PD1 targeted NPs were able to target ~6% of PD1 expressing T cells 
vs ~1% for non-targeted NPs within B16F10 tumors 1 hour post iv administration. These results 
emphasize the potential for targeted NPs to interact with T cells and thus deliver drug cargos. 
Due to iRAE and the requirement for repeated dosing in clinical ICB therapeutic protocols, 
drug delivery platforms that improve mAb delivery to the tumor and achieve sustained release 
have garnered recent interest. To this end, microparticle-based formulations aiming to prolong the 
retention of therapeutic agent at the site of injection have emerged as an attractive strategy since 
increasing carrier size enhances and prolongs retention at the site of injection (89, 148). Material 
systems can additionally be engineered to control the release of agent from its carrier in order to 
prolong its therapeutic effects. For example, Rahimian et al. engineered microparticles ~10-25 μm 
in diameter composed of a biodegradable poly(lactic-co-hydroxymethyl-glycolic-acid) polymer 





the authors deemed optimal allowed for a burst release of about 20% of loaded mAb followed by 
a sustained release of the remaining 80% of mAb over approximately 30 days (149). When 
compared to the same dose of mAb formulated in an incomplete Freund’s adjuvant formulation, 
the mAb-loaded microparticle system resulted in serum mAb levels that were significantly lower 
(5-10 fold) than the mAb administered in incomplete Freund’s adjuvant. Microneedle (MN)-based 
platforms may be an appealing administration strategy to improve mAb retention due to its ease 
of administration on superficial tumors such as those of the skin, and potential to more 
homogenously distribute therapeutic agent throughout the target tissue. Wang et al. and Ye et al. 
utilized MN to deliver nanoparticles composed of hyaluronic acid or dextran-alginate that 
encapsulate anti-PD-1 mAb and other small molecule therapeutics (150, 151). In this engineered 
MN system, the release of anti-PD-1 mAb from the nanoparticles was stimuli responsive to either 
hyaluronidase, an enzyme overexpressed in the tumor microenvironment (152) or glucose-
triggered reductions in local pH. These MN-based approaches resulted in sustained anti-PD-1 mAb 
retention within the tumor, leading to a more robust immunotherapeutic response indicated by 
enhanced T cell infiltration into the tumor, reductions in tumor growth, and prolonged animal 
survival (150, 151). Another approach is the use of hydrogel-based platforms to improve release 
kinetics of delivered mAb. Wang et al. recently demonstrated that a s.c. injected alginate hydrogel 
improved the anti-tumor activity of both celecoxib and anti-PD-1 mAb when used individually or 
combined (58). It is interesting to note that this system did not lower the serum concentration of 
anti-PD-1 mAb compared to an i.p. injection of free mAb (58). However, the accumulation within 
the B16F10 melanoma was much higher compared to i.p. infusion (58). Another approach 
developed to improve immune checkpoint mAb accumulation within tumors and resulting 
therapeutic effects is piggybacking on the intrinsic capacity of platelets to accumulate at wound 





bifunctional maleimide linker and demonstrated the release of anti-PD-L1 mAb via platelet-
derived microparticles following platelet activation or adhesion (155). This approach improved 
survival and tumor suppression compared to i.v. injection of free anti-PD-L1 mAb in both 
melanoma and breast cancer models (155). Taken together, these drug delivery approaches show 
great promise in improving checkpoint blockade by enhancing payload delivery without the need 







CHAPTER 3. BLOCKADE OF IMMUNE CHECKPOINTS IN 
LYMPH NODES THROUGH LOCOREGIONAL DELIVERY 
AUGMENTS CANCER IMMUNOTHERAPY 
 
3.1 Introduction 
Immune checkpoint blockade (ICB) using monoclonal antibodies (mAbs) specific to cytotoxic T 
lymphocyte antigen 4 (CTLA4) and programmed cell death 1 (PD1) or its ligands has emerged as 
one of the most promising new approaches in cancer immunotherapy to invigorate anti-tumor 
immunity (156–159). CTLA4 is a transmembrane receptor found constitutively on regulatory T 
cells (Tregs) and is limited in its expression by CD4 and CD8 T cells immediately following 
engagement of the T cell receptor. CTLA4 directly competes with CD28 for B7 ligand binding on 
antigen-presenting cells (APCs), consequently leading to T cell anergy (160). Similarly, surface 
expression of PD1 is broadly induced following T cell activation and PD1 is thought to function 
in peripheral tissues through its binding interactions with programmed death ligands (PDL1 and 
PDL2) found on many cell subtypes including predominantly, but not limited to, tumor cells and 
APCs, respectively. Following PD1:ligand engagement, T cell function is dampened; an effect that 
protects the host during viral infection from immune-mediated tissue destruction leading to T cell 
exhaustion (161). By blocking these inhibitory pathways using function blocking mAbs, activation 
and cytotoxic capabilities of T cells can be restored (156, 161). 
Although the canonical view on ICB therapy effects is that they are mediated primarily 
within the tumor microenvironment (TME) by restoring anti-tumor functions of infiltrating T cells, 
evidence of the pleotropic effects of ICB mAbs continues to amass. Specific isotypes of anti-
CTLA4 (aCTLA4) (IgG2a) mediate the depletion of tumor resident Tregs (trTregs) via antibody 





anti-PD1 (aPD1) has been shown to restore the effector functions of CD8 and CD4 T cells (2), 
CD28 stimulation is required for aPD1 efficacy, suggesting a role of B7-expressing APCs (162). 
aPD1 has also been shown to modulate a stem-like CD8 T cell population capable of proliferating 
and giving rise to T cells of a tumor killing effector-like phenotype (9, 10, 163–166). Furthermore, 
PDL1 expression on tumor cells is not required for disease progression and aPD1 efficacy in 
certain cancer types (167–169). Both aCTLA4 and aPD1 therapy have also been shown to broaden 
the repertoire of tumor specific CD8 T cell clones (40, 170–172), which is associated with 
improved clinical outcomes (173, 174). Solely blocking checkpoint pathways in the TME may 
thus not be sufficient to generate high response rates following ICB therapy. 
To this end, appreciation for lymphoid tissues as critical in the generation of effective 
immunotherapy responses is increasing (175, 176). CD103+ APCs transport antigen to tumor 
draining lymph nodes (TdLNs) where they can prime naïve CD8 T cells (177, 178). Moreover, 
TdLNs are involved in mediating the effects of aCTLA4 (179) and aPD1 therapy (180). The 
presence of the aforementioned stem-like CD8 T cell compartment has been observed in mouse 
and human LNs, in addition to the TME, suggesting these tissues as a potential source of tumor 
infiltrating lymphocytes (TILs) (181). However, the TME and TdLNs are poorly accessed using 
systemic drug administration (83, 182, 183), the predominant route used in both preclinical tumor 
models and human patients, which may limit drug effects. Clinical studies have reported dose-
efficacy relationships of aCTLA4 and aPD1 therapies (52, 57). Increasing the availability of ICB 
mAb within target tissues, including the TME and lymphoid tissues that are enriched in tumor-
specific T cells, thus has the potential to improve ICB therapy.  
Previous reports have described improvements in anti-tumor responses using intratumoral 
(i.t.) administration routes compared to traditional systemic administration (132, 184, 185). 





tumoral administration has previously been investigated (179, 186) and subcutaneous (s.c.) 
administration is being explored in the clinic (8). It is of interest to note that mAbs are large 
molecules (150 kilodaltons) and thus are transported differently than traditional small molecule 
drugs or other smaller biologics. Specifically, injection of compounds similarly sized to mAbs into 
the interstitium of peripheral tissues usually results in clearance from the injection site via the 
initial lymphatics and thus accumulation of such compounds in draining LNs (144). We 
hypothesized that mAbs would behave similarly and therefore utilizing direct administration into 
peripheral tissues would improve LN delivery of mAbs allowing for improvement of ICB 
therapeutic effects. Our results in three preclinical solid tumor models (utilizing melanoma and 
breast cancer cell lines) support the hypothesis that modulation of immune checkpoint pathways 
in (Td)LNs using locoregional administration of ICB mAbs leads to enhanced anti-tumor efficacy, 
enables dose-sparing, and has the potential to reduce treatment-induced toxicity compared to 
systemic drugging. 
3.2 Results  
3.2.1 Tumor-directed ICB augments therapeutic responses locally  
To evaluate whether augmenting the accumulation of administered mAb drug within target 
tissues can improve the effects of ICB, survival studies were performed in a poorly ICB responsive 
tumor model (B16F10 melanoma) using both aCTLA4 and aPD1 mAbs and comparing 
intraperitoneal (i.p.) versus i.t. routes of administration. Modest reductions in tumor growth were 
induced by i.p. administration of ICB mAb, however administration i.t. instead resulted in 
profound reductions in tumor growth (Fig. 4A). To explore the potential effects on priming and 
expansion of T cells in response to endogenous tumor antigen, the systemic response of untreated 
tumors in the contralateral (c.l.) dorsal skin was concurrently monitored. Strikingly, untreated 





The net effect was a substantial prolonging of mouse survival with i.t. compared to i.p. 
administration of ICB mAb (Fig. 4C). These data demonstrate the capacity of tumor-localized ICB 
therapy to elicit a systemically functional anti-tumor immune response that exceeds the effects of 
systemically administered ICB therapy.  
 
The immunological mechanisms underlying the therapeutic responses seen with i.t. and i.p. 
ICB therapy (aCTLA4 and aPD1 in combination) were explored. T cell phenotypes in i.t. saline 
(control) or ICB treated animals bearing single B16F10 tumors were analyzed 12 d post tumor 
implantation. Administration i.t. led to a dramatic reduction in tumor burden (Fig. 5A) and was 
associated with a reduction in trTregs frequencies (Fig. 5B), which can attributed to the particular 
aCTLA4 clone used (37–39). As is well characterized in many preclinical melanoma models and 
human patients, ICB therapy was associated with an increase in CD8 TILs, although this effect 
was limited to i.t. administration here (Fig. 5C). Interestingly, of these CD8+ TILs, the levels of 
granzyme B producing (Fig. 5D) and effector (KLRG1+) cell frequencies (Fig. 5E) were similar 
between i.p. and i.t. administration, suggesting effective therapy is associated with increased 
frequencies of CD8 TILs rather than reinvigoration of exhausted TILs. To explore the source of 
Figure 4: Intratumoral administration of ICB promotes systemic antitumor immunity. 
Figure 4: Intratumoral administration of ICB promotes systemic antitumor immunity. 
Following B16F10 implantation, mice were administered 150 µg of aPD1 and aCTLA4 
(9H10) on d 5, 7, and 9 post tumor implantation i.p. or i.t.. (A) Tumor growth curve of primary 
tumor (d 0 tumor implant, i.t. treated tumor). (B) Tumor growth curve of secondary tumor (d 
2 tumor implant, non-treated i.t. tumor). (C) Survival curves of mice. Combined data of two 
independent repeats (total n=10, mean + SEM). Statistical analyses were done using ANOVA 
with Tukey’s test. Log-rank (Mantel-Cox) test for survival curves. *p < 0.05, **p < 0.01, ***p 
< 0.001, ****p < 0.0001.  







































































CD8 TILs, the levels of proliferation through Ki-67 expression were measured. Cycling CD8 T 
cells frequencies were found to be elevated in the TME and TdLN using i.t. administration with 
comparable increases observed in the spleen between i.p. and i.t. administration as well as minimal 
changes in the non-TdLNs (nTdLNs) (Fig. 5F-G). Frequencies of CD8 T cells within each tissue 
compartment exhibiting stem-like (PD1+Tcf1+Tim3-) versus effector-like (PD1+Tcf1-Tim3+) CD8  
Figure 5: Tumor-bearing mice administered ICB intratumorally exhibit unique T 


































































































































































































































T cell phenotypes were also assessed. The phenotypes of activated (PD1+) CD8 T cells were found 
to predominately be effector-like in the TME compared to stem-like in the LNs with a balance in 
between in the spleen regardless of therapy or route of administration (Fig. 5H).  
Similar trends for Ki-67+ frequencies were also observed in the CD4 T cell compartment 
(Fig. 6).  
 
Of note, ex vivo staining confirmed that therapeutic aPD1 mAb did not block the binding 
of aPD1 mAb used for flow cytometry staining (Fig. 7). These data support the concept that ICB 
Figure 6: Changes in CD4 T cell compartment resulting from ICB. 
Figure 5: Tumor-bearing mice administered ICB intratumorally 
exhibit unique T cell changes in TME, TdLN, and Spleen. (A) B16F10 
tumor growth over first 12 d with 150 µg of ICB mAb [combination of aPD1 
and aCTLA4 (9H10) administered on d 5, 7, and 9 post tumor implantation. 
(B) Frequencies of CD4+ FoxP3+ T cells. (C) Frequencies of CD8+ T cells 
in TME. Frequencies of granzymeB+ (D) and KLRG1+ (E) CD8+ T cells 
in TME. Frequencies of Ki-67+ CD8+ T cells in TME (F) and lymphoid 
tissues (G). (H) Frequencies of “stem-like” (Tcf1+Tim3-) vs “effector-like” 
(Tcf1-Tim3+) CD8 T cells, pregated on PD1+, in the TME, nTdLNs, TdLNs, 
and spleen. Data represent one or two independent experiments (n=4-10, 
mean ± SD) Statistical analyses were done using ANOVA with Tukey’s test. 
*p < 0.05, **p < 0.01. n.s., not significant. 
Figure 6: Changes in CD4 T cell compartment resulting from ICB. (A) 
Frequencies of CD4h (CD4+ FoxP3-) TILs. (B) Frequencies of Ki-67+ CD4+ 
FoxP3- TILs. (C) Frequencies of Ki-67+ CD4+ FoxP3- T cells in lymphoid tissues. 
Data represent two independent experiments (n=8-10 mice, mean ± SD), n.s., not 
significant relative to each group in each tissue. Statistical analyses were done using 
































































































efficacy is in part mediated by increasing the frequencies of TILs that may originate from the TME 
or peripheral tissues including the TdLN or spleen. 
 
3.2.2 Administration route affects mAb biodistribution 
Considering responses were observed in secondary lymphoid tissues in addition to the 
TME following i.t. administration, the effect of route of administration on levels of mAb 
accumulation within the spleen, LNs (tumor-draining or non-draining), and TME as well as other 
Figure 7: Therapeutic and staining aPD1 antibodies can simultaneously stain PD1-
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Sample Name Subset Name Count
Cells_Ion,2f,PMA control_007.fcs CD3 35352 
Cells_Ion,2f,PMA Block_008.fcs CD3 33552 












Figure 7: Therapeutic and staining aPD1 antibodies can simultan usly stain PD1-expressing 
T cells. (A) Representative flow cytometry plots of splenocytes from each staining group gated on 
live cells. (B) Histogram and quantification of PD1 expression on CD3+ T cells following 
activation with ionomycin+PMA using no stain (FMO), BV785 labeled aPD1 (Biolegend, clone: 
29F.1A12) stain, or incubation with non-fluorescent aPD1 (BioXCell, clone: RMP1-14) followed 
by BV785-aPD1 (Biolegend, clone: 29F.1A12) stain. (C) Quantification of B. Data represents 





systemic tissues was assessed. Levels of AlexaFluor647 labeled aPD1 or aCTLA4 mAb (Fig. 8A) 
were measured following a single dose using four different administration routes; i.p., in the 
forelimb contralateral to the tumor (c.l.), in the forelimb ipsilateral to the tumor (i.l.), and i.t. 5 d 
post B16F10 tumor implantation (Fig. 9A). Tumor mAb levels were found to be sustained over 24 
h using an i.t. injection but were near the limit of detection using other administration routes (Fig. 
9B-C). Levels of mAb in the blood and spleen were equivalent between administration routes (Fig. 
9C-D). When assessing mAb levels in LNs, i.p. administration resulted in minimal accumulation 
in any measured LN, whereas c.l. administration led to accumulation within nTdLNs (Fig. 9E-F). 





TdLNs (Fig. 9E-F). These locoregional administration routes allowed for reduced dosing while 
maintaining mAb accumulation within TdLNs (Fig. 9G-H). Accumulation of mAb in dLNs was  
 
Figure 8: Characterization of mAb labeling and accumulation within LNs and binding of LN T cells 
after administration. 









































































Figure 8: Characterization of mAb labeling and accumulation within LNs and binding of 
LN T cells after administration. (A) Representative size exclusion chromatography curve of 
Alexa Fluor 647 labeled antibody elution from sepharose CL-6B. Box indicates collected fractions 
that were concentrated for in vivo use. (B) LN distribution of unlabeled aCTLA4 (9H10) mAb 24 
hr post injection and stained ex vivo with fluorescently conjugated secondary antibody (TdLN 
from uninjected animals as control, TdLN from i.p. or i.l injected animal, nTdLN from c.l. injected 
animal). (C) Quantification of aCD3 binding to CD3 expressing T cells at different time points 
following collagenase D treatment and LN mechanical disruption. Data represents one experiment 
(total n=2, mean ± SD)). n.s., not significant. Statistical analyses were done using ANOVA with 





not an effect of dye labeling as administered non-fluorescent mAb was observed to accumulate 
within dLNs as with AlexaFluor647 tagged mAb (Fig. 8B). Using these four different routes of 
administration allowed for subsequent studies to explore the effects on drugging particular tissues 
of interest and their effects on ICB therapeutic efficacy. 
 
To explore whether lymph-delivered mAb had access to LN T cells, aCD3 (in place of 
immune checkpoint targeting) mAb was administered in the forelimb to target LN-resident CD3 
expressing T cells. A gradual increase in T cell labeling was observed over 24 hr, with nearly 
100% of T cells labeled with AlexaFluor647-aCD3, suggesting a diffusion-limited intra-LN 
transport process as comparable total LN mAb concentrations were observed within LNs at all 
time points (Fig. 9I). The measured LN mAb concentration was sufficient to label ~100% of T 
cells when LNs were mechanically and enzymatically degraded after resection (Fig. 8C). These 
Figure 9: Directed mAb delivery to various tissues with different routes of administration. 
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Figure 9: Directed mAb delivery to various tissues with different routes of 
administration. Measured tissue levels of AF647-labelled aPD1 or aCTLA4 (9H10) mAb. 
(A) Injection sites and color scheme. (B) mAb signal (IVIS quantification) in TME over 24 hr 
post injection. (C) mAb concentration in tumor, blood, and spleen 24 hr post injection. (D-E) 
Representative IVIS images of mAb levels in spleens (D) and LNs (E). (F) mAb 
concentrations in LNs 24 hr post injection. (G-H) Measured levels of AF647-labelled aPD1 or 
aCTLA4 in TdLNs using different mAb doses. (G) Representative IVIS images of mAb levels 
in TdLNs. (H) Quantification of G. (I) Concentration of aCD3 (purple – left axis) and 
frequencies of T cell labeling of injected aCD3 (black – right axis) in LNs draining forearm 
i.d. injection. Data represent two independent experiments (total n=5, mean ± SD). Statistical 





results are in line with a recently published study confirming mAb has access to LN cells (187). 
Overall, these results demonstrate various administration routes can be used as an approach to 
direct the delivery of mAb to T cells in specific tissues including the TME, LNs, and systemic 
tissues.   
3.2.3 TdLN targeted ICB improves anti-melanoma response  
 
To elucidate the mechanistic effects of modulating immune checkpoints in various tissues 
on anti-tumor immunity, ICB mAbs were administered in a similar scheme as reported in Fig. 9. 
This approach allowed the effects of ICB mAb delivery to specific tissues to be elaborated as i.t. 
administration results in appreciable mAb accumulation within the TME, TdLN, and spleen, i.d. 
forelimb injections target only the TdLN or nTdLN and spleen, and i.p. administration results in 
only accumulation in the spleen but not the TME nor LNs. On d 5 following B16F10 melanoma 
implantation, mice were treated with various ICB therapeutic regimens and treated every other 
Figure 10: ICB directed towards TdLN potentiates ICB therapeutic effects in melanoma. 
Figure 10: ICB directed towards TdLN potentiates ICB therapeutic effects in melanoma. 
B16F10 tumor growth (A,C,E) and animal survival (B,D,F) after aPD1 monotherapy (A-B), 
aCTLA4 (9H10) monotherapy (C-D), and aPD1+aCTLA4 (9H10) therapy (E-F) using 150 µg 
of each mentioned mAb. Data represent at one, two, or three independent experiments (total 
n=5-15, mean + SEM). Statistical analyses were done using ANOVA with Tukey’s test. Log-
rank (Mantel-Cox) test for survival curves. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 
0.0001. 







































































































































































































































































A aPD1 C aCTLA4 E aPD1 + aCTLA4
B aPD1 D aCTLA4 F aPD1 + aCTLA4
G c.l. H i.l. I i.t.






day, including aPD1, aCTLA4, or the combination of the two, for a total of three doses. When 
used as monotherapies, aPD1 and aCTLA4 administered i.p. and in the forelimb c.l. to the tumor 
had minimal effect on tumor growth and animal survival, whereas administration of ICB in the 
forelimb i.l. to the tumor and i.t. reduced tumor growth during treatment to equivalent extents, 
which in the case of aCTLA4 monotherapy led to prolonged survival (Fig. 10A-D). However, ICB 
therapy was less effective in larger sized tumors (Fig. 11). Similar effects were observed when 
aPD1 was combined with aCTLA4, with c.l. administration resulting in reduced tumor growth 
during treatment (Fig. 10E-F). Overall, these data suggest that targeting of TdLNs alone (or alone 
in addition to the spleen) results in the generation of robust anti-tumor immunity much greater than 
that of systemic administration.  
 
Figure 11: ICB therapy is less effective in larger tumors. 
Figure 11: ICB therapy is less effective in larger tumors. (A) C57Bl6 mice were implanted 
with 5 x 105 B16F10 cells on d 0 and treated on d 5, 7, and 9 mice with 150 µg of aPD1 mAb 
i.p. or i.t.. (B) Survival curves. Data represents one experimental test (total n=5). Log-rank 
(Mantel-Cox) test for survival curves. n.s. not significant. 
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3.2.4 Locoregional ICB improves vaccination therapy 
 
We next explored administration effects using ICB therapy in combination with a model 
tumor vaccine. The rationale was to first develop and expand a robust anti-tumor CD8 T cell pool 
in tumor-bearing animals prior to modulation of T cell activation and effector functions resulting 
from ICB. Mice bearing B16F10 melanomas expressing ovalbumin (OVA) were vaccinated i.d. in 
Figure 12: mAb directed to tumor and TdLNs in combination with vaccination improve therapeutic effects of ICB. 
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Figure 12: mAb directed to tumor and TdLNs in combination with vaccination 
improve therapeutic effects of ICB. (A) B16F10-OVA treatment schedule and color 
scheme. Vaccination was performed by intradermal administration 3 µg of CpG and 
10 µg of OVA in each limb d 4 & 10. 150 µg of ICB mAb [aPD1 and aCTLA4 (9H10) 
in combination] using indicated administration routes d 5, 8, 11, & 14. (B) Tumor 
growth during treatment window. (C) Animal survival curves. (D-F) Tumor volume 
(x-axis) versus T cell infiltration levels (y-axis): (D) CD8+/CD4+FoxP3+ TIL ratio, 
(E) CD8+ frequency of CD3+ TILs, (F) CD4+ FoxP3+ frequency of CD3+ TILs. (G) 
Frequencies of Ki-67+ CD4+ FoxP3+ in TME. (H) Frequencies of CD8+ T cells in 
TME. Frequencies of Ki-67+ CD8+ T cells in TME (I) and lymphoid tissues (J). Data 
represent one, two, or three independent experiments (total n=4-14, mean ± SD). 
Statistical analyses were done using ANOVA with Tukey’s test. Log-rank (Mantel-





each limb with OVA protein as tumor antigen with CpG oligodeoxynucleotide (CpG) as an 
adjuvant 4 and 10 d post tumor implantation prior to ICB administration (aPD1 and aCTLA4) on 
d 5, 8, 11, and 14 (Fig. 12A). Irrespective of route of mAb administration, ICB improved vaccine 
effects during treatment, as measured by tumor outgrowth over the first 16 d (Fig. 12B). After 
cessation of therapy, ICB administered in the skin (either i.t. or i.d.) conferred improved survival 
(Fig. 12C) to that of systemically administered ICB (i.p.). T cell phenotyping d 16 post tumor 
implantation revealed that increased CD8/Treg ratios and CD8 T cell infiltration correlated with 
smaller tumors (Fig. 12D-E) while increased Treg frequencies correlated with increased tumor size 
(Fig. 12F). ICB administered i.t. led to reductions in proliferating Tregs (CD4+FoxP3+Ki-67+) 
within the tumor compared to other ICB administration methods (Fig. 12G), an effect due to the 
particular aCTLA4 clone used and from higher CTLA4 surface expression on Tregs (Fig. 13).  
 
Interestingly, when mice were treated with ICB therapy, increased infiltration of CD8 TILs 
was observed (Fig. 12H). However, similar levels of CD8 TIL proliferation were observed 
Figure 13: Tregs in TME express CTLA4 at higher levels 
than helper CD4 and CD8 T cells. 
Figure 13: Tregs in TME express CTLA4 at higher levels than helper 
CD4 and CD8 T cells. (A) 16 d following B16F10-OVA implantation and 
treatment, mice were sacrificed and tumor resident T cells were analyzed for 
CTLA4 expression. Tregs defined as CD4+ FoxP3+ and CD4h T cells as 
CD4+ FoxP3-. Data represent one experiment (total n=8, mean ± SD). 
Statistical analyses were done using ANOVA with Tukey’s test. ***p < 0.001, 



































regardless of therapy or route of administration (Fig. 12I). Instead, increases in proliferation were 
observed in lymphoid tissues, specifically the TdLN using an i.d. or i.t. administration and the 
spleen with the addition of ICB therapy (Fig. 12J). Similar to results exploring the cell state of 
PD1+ CD8 T cells (Fig. 5), the PD1+ CD8 T cells within the TME were predominately effector-
like cells whereas lymphoid tissues consisted of both effector- and stem-like CD8 T cells (Fig. 14). 
Furthermore, CD8 T cells generated in LNs and spleen with ICB therapy were functional and 
capable of responding to tumor antigen upon ex vivo restimulation (Fig. 14). Similar trends were 
observed in the CD4 helper compartment (Fig. 15). Taken together, these results are in line with 
those from neoadjuvant studies where improved responses are associated with increased CD8 T 
cell proliferation and tumor infiltration (Fig. 5), which was achieved via concurrent drug 
modulation of immune checkpoint pathways in the TME and LN. 
Figure 14: ICB therapy modulates CD8 T cells in various tissues leading to effector cell phenotypes. 
Figure 14: ICB therapy modulates CD8 T cells in various tissues leading to effector cell 
phenotypes. 16 d following B16F10-OVA implantation, mice were sacrificed and CD8 T cells were 
analyzed for “stem-like” (PD1+ CXCR5+ CD39-) or “effector-like” (PD1+ CXCR5- CD39+) 
phenotypes. (A) TME. (B) nTdLNs. (C) TdLNs. (D) Spleen. E-F) Frequency of effector molecule 
producing SIINFEKL specific CD8 T cells in TdLNs (E) and spleen (F). A-D represents one 
experiment (n=3-5, mean ± SD). E-F represent two independent experiments (n=8-10, mean ± SD). 
Statistical analyses were done using ANOVA with Tukey’s test. * represents significance, *p < 0.05, 
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3.2.5 Dose sparing achieved by LN and TME directed ICB 
Considering the dose-toxicity relationship of ICB therapy, we assessed ICB efficacy in a 
dose de-escalation study using aPD1 and aCTLA4 (Fig. 16). Dose-limited therapeutic effects were 
observed in the case of nTdLN (c.l.) and TdLN (i.l.) drugging while i.t. administration did not 
display a dose-efficacy relationship (Fig. 16). This may be explained by our observations of 
Figure 15: ICB with vaccination promotes CD4h activation in TdLNs. 
Figure 15: ICB with vaccination promotes CD4h activation in TdLNs. (A) Frequencies of 
CD4+ FoxP3- T cells in the TME. Frequencies of Ki-67+ CD4+ FoxP3- T cells in TME (B) and 
lymphoid tissues (C). D-E) Frequency of cytokine producing OVA specific CD4 T cells in spleen 
(D) and TdLNs (E). Data represent one or two independent experiments (n=4-10 mice, mean ± 
SD). Statistical analyses were done using ANOVA with Tukey’s test. *p < 0.05, **p < 0.01, ***p 







































































































































substantial reductions in trTregs levels following i.t. administration (Fig. 5B, Fig. 12G), which is 
in line with multiple other reports showing that the efficacy of aCTLA4 therapy is due in part to 
the depletion of trTregs when an IgG2a clone is used. However, Treg depletion by aCTLA4 has 
not been observed in the clinical setting and instead clones of aCTLA4 used in human patients 
have been shown to act predominately via CTLA4 receptor blockade and favoring CD28 ligation 
(188, 189), i.e. without measurable Treg depletion. We therefore investigated the therapeutic 
effects of CTLA4 blockade using a clone of an IgG1 isotype (4F10) using an identical dosing 
schedule to those conducted using the Treg-depleting (IgG2a isotype) aCTLA4 clone (Fig. 10). 
Using this non-Treg depleting aCTLA4 clone (IgG1), i.p. and c.l. administration had minimal anti-
tumor therapeutic effects (Fig. 17A-B, E-F). Conversely, both i.l. and i.t. administration elicited 
robust anti-tumor therapeutic effects even at the lowest tested dose (12.5 µg, Fig. 17C-D, G-H). 
These data thus demonstrate that the benefits of LN targeting are applicable to multiple aCTLA4 
mAb clones with differing immune modulatory mechanisms. More interestingly, these results 
suggest that the efficacy of ICB directed to the TdLNs alone or in addition to the TME is roughly 
equivalent, at least at these tested doses in this model, pointing to LNs mediating the expansion of 






Figure 16: ICB directed to tumor and/or TdLN potentiates ICB therapeutic effects independent of tumor resident Treg 
depletion. 
Figure 17: ICB directed to TME and/or TdLN allows for dose reductions. 
Figure 16: ICB directed to TME and/or TdLN allows for dose reductions. B16F10 tumor 
growth (A,C,E) and animal survival (B,D,F) using aPD1+aCTLA4 (9H10) mAb therapy at 
various doses; (A-B) c.l. administration, (C-D) i.l. administration, (E-F) i.t. administration. Data 
represent one experiment (total n=5, mean + SEM). Statistical analyses were done using ANOVA 
with Tukey’s test. Log-rank (Mantel-Cox) test for survival curves. *p < 0.05, **p < 0.01, ***p < 
0.001, ****p < 0.0001. 

































































































































Figure 17: ICB directed to tumor and/or TdLN potentiates ICB therapeutic effects 
independent of tumor resident Treg depletion. B16F10 tumor growth (A - D) and animal 
survival (E - H) after ICB therapy using 150, 50, or 12.5 µg of aPD1 (clone: RMP1-14) in 
combination with aCTLA4 (clone: 4F10); (A,E) i.p. administration, (B,F) c.l. administration, 
(C,G) i.l. administration, and (D,H) i.t. administration. Combined data of two independent 
repeats (total n=10, mean + SEM). Statistical analyses were done using ANOVA with Tukey’s 
test. Log-rank (Mantel-Cox) test for survival curves. *p < 0.05, **p < 0.01, ***p < 0.001, ****p 
< 0.0001. 
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3.2.6 ICB targeted to TdLNs improves therapeutic effects in breast cancer 
To extend these results beyond melanoma models, two different mammary carcinoma 
models, the E0771 and 4T1, were implanted orthotopically in the 4th mammary fat-pad. These 
implantation sites generate different TdLNs, specifically the ipsilateral inguinal (primary draining) 
and axillary (secondary draining) LNs. In order to deliver mAb to TdLNs or nTdLNs, mAb 
administration was performed in the flanks of mice (Fig. 18A) while the systemic i.p. 
administration was kept the same and i.t. administration is administered to the mammary fat-pad 
tumor site. Following administration of fluorescently labeled mAb (aPD1), i.t. administration 
resulted in substantial mAb retention in the TME while other administration routes resulted in low 
to minimal TME concentrations (Fig. 18B). Levels of mAb accumulation in the spleen were found 
to be equivalent regardless of administration route (Fig. 18B). Contrastingly, i.l. and i.t 
administration of mAb (aPD1 or isotype) led to higher TdLN accumulation while c.l. 
administration led to accumulation within nTdLN (Fig. 18B).  
In the context of ICB with aPD1 in the E0771 model, locoregional therapy was found to 
somewhat hasten responses, in particular with i.l. administration (Fig. 19A-B). However, the 
effects of aPD1 monotherapy, irrespective of the administration route, were less efficacious in 
prolonging survival, motivating the exploration of aPD1 use in combination with aCTLA4. To this 
end, a single dose of aPD1 in combination with aCTLA4 (clone: 9H10) administered i.t., i.l., and 
c.l. resulted in substantial reductions in tumor growth compared to both no treatment and systemic 
i.p. administration (Fig. 18C). However, substantial improvements in survival were found for this 
combination therapy (40-60% overall complete response) and were comparable between all 
administration routes (Fig. 18D). Dose de-escalation studies demonstrated that survival was highly 





(Fig. 19C-F). This data demonstrates that the therapeutic benefits of ICB with aPD1 in this model 
can be substantially augmented by aCTLA4, which is unsurprising given this aCTLA4 clone’s 
pleotropic effects on the anti-tumor immune response. 
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Figure 18: TdLN targeted ICB exhibits robust antitumor therapeutic effects in breast 
tumor models. (A) Image of administration sites and color scheme. (B) mAb concentrations 
in TME, spleen, and LNs in E0771 tumor-bearing animals 24 hr post injection. (C) Growth 
curves of E0771 tumors using single a 100 µg dose of aPD1+aCTLA4 (clone: 9H10) when 
tumors reached approximately 100 mm3. (D) Survival of animals treated in panel C. (E) Growth 
curves of E0771 tumors with 30 µg aPD1+aCTLA4 (clone: 4F10) therapy on d 10, 14, and 20. 
(F) Survival of animals treated in panel E. (G) Growth curves of 4T1 tumors treated with 50 
µg aPD1 and aCTLA4 (clone: 4F10) on d 7. (H) Survival of animals treated in panel G. B 
represents one or two independent experiments (total n=4-9, mean ± SD), C/D represent two 
independent experiments (total n = 11, mean ± SEM), E-H represent one experiment (total 
n=4-8, mean ± SEM). Statistical analyses were done using ANOVA with Tukey’s test. Log-






To decouple the effects of trTreg depletion versus expansion of CD8 T cell immunity 
associated with aCTLA4 treatment, the effects of the 4F10 clone of aCTLA4 that does not result 
in trTreg depletion were evaluated (Fig. 18E-F). Unsurprisingly, anti-tumor therapeutic efficacy 
in all tested administration routes was found overall to be much less effective, indicative of a major 
role that Tregs play in the immune physiology of the E0771 model. However, i.l. and i.t. 
administration did substantially suppress tumor growth as well as prolong survival compared to 
i.p. and c.l. administration (Fig. 18E-F). Effects of aPD1 in combination with aCTLA4 (clone: 
4F10) in the highly metastatic 4T1 model were also tested. Improved responses were observed 
with c.l., i.l., and i.t. therapy compared to that of systemic i.p. therapy (Fig. 18G-H) with no signs 
of metastasis in responding mice (Fig. 19G-H). Notably, when the trTreg depleting aCTLA4 clone 
(clone: 9H10) was used, systemic therapy was just as effective as administration in the skin (both 
i.l. and c.l., Fig. 19I-J). This data is suggestive of these breast tumor models being highly infiltrated 
with Tregs that are implicated in tumor progression. Nevertheless, as was found in the B16F10 
melanoma model, (Td)LN targeting of mAb improved therapeutic responses to ICB in two breast 






3.2.7 Locoregional administration reduces toxicities of ICB 
ICB is associated with immune related adverse events that can lead to discontinuation of 
treatment, especially when aPD1 and aCTLA4 are combined (7). Following completion of 
treatment in each therapeutic regimen, blood was collected 2-3 d following the last mAb 
administration and serum analyzed. When treated with ICB alone, i.p. administration led to 
elevated alanine transaminase serum levels compared to no treatment and cutaneous injections in 
both the B16F10 and E0771 tumor models (Fig. 20A). When mice were vaccinated, similar trends 
were observed as measured on d 16 post tumor implantation (Fig. 20B). Furthermore, mAb 
concentration in the liver, kidneys, and lungs was proportional to the administered dose of ICB 
Figure 19: Effective ICB therapy in breast cancers requires aCTLA4. 
Figure 19: Effective ICB therapy in breast cancers requires aCTLA4. (A) Growth curves of 
E0771 tumors with 100 µg aPD1 monotherapy on d 10, 14, and 17. (B) Survival curve of aPD1 
monotherapy. C-F) Survival curves of E0771 tumors according to administration route with 10, 
30, or 100 µg aPD1+aCTLA4 (clone: 9H10) therapy starting when tumors reached 100 mm3 (d 10 
or 12) and continued on d 14 and 20 or 16 and 22 pending start date: (C) i.p. administration, (D) 
c.l. administration, (E) i.l. administration, (F) i.t. administration. (G) Size of LNs at endpoint for 
tumor bearing mice and d 80 for surviving mice. (H) Size of LNs at endpoint for tumor bearing 
mice and d 80 for surviving mice. (I) Growth curve of 4T1 tumors using 50 µg aPD1+aCTLA4 
(9H10) on d 7 and 10. (J) Survival curve of 4T1 mice. Data represent one experiment (total n=4-
5, mean ± SEM). Statistical analyses were done using ANOVA with Tukey’s test. Log-rank 
(Mantel-Cox) test for survival curves. *p < 0.05, **p < 0.01, n.s., not significant. 
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mAb (Fig. 20C, S21). Overall, these results suggest that locoregional administration of ICB mAb, 
which can elicit robust immunity and anti-tumor efficacy, results in reduced toxicity associated 
with systemic and high dose ICB therapy. 
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Figure 21: Locoregional administration reduces ICB-associated toxicities. 
Figure 20: Locoregional administration reduces ICB-associated toxicities. ALT levels from 
serum of animals (A) d 12 post B16F10 implantation or d 22 post E0771 implantation and (B) d 
16 post tumor implantation in B16F10-OVA bearing animals following vaccination. (C) 
Concentration of mAb in liver 24 hr post i.p. administration at various total doses. Naïve: tumor-
free mouse. PBS was administered i.t. In A; closed circles represent B16F10 experiments while 
open circles represent E0771 experiments. A) represents one experiment in each tumor model 
(total n=10, mean ± SD), B) represents at least two independent experiments (total n=6-16, mean 
± SD), C) represents one experiment in B16F10 bearing mouse (n=2). Statistical analyses were 
done using ANOVA with Tukey’s test. *p < 0.05, **p < 0.01. 


































































Figure 21: mAb accumulation in systemic tissues proportional to administered dose. 
24 hr post administration using aPD1, mice were sacrificed and tissues harvested to 
measure concentrations of accumulated mAb. (A) Kidneys. (B) Lungs. Data represent one 





3.3 Discussion  
ICB has emerged as a promising new class of anti-cancer therapy, but these treatments are 
associated with low response rates and substantial toxicities, which may be related to systemic 
administration of these drugs. Targeting the TME versus LNs and spleen using different 
administration routes and doses was explored in order to increase mAb accumulation within these 
tissues and therefore modulate these pathways at the effector and priming phases, respectively. In 
three tumor models, varying from poorly to highly responsive to ICB, administration routes that 
result in pronounced levels of mAb accumulation in (Td)LNs led to superior therapeutic effects on 
tumor control compared to those achieved by systemic administration. 
A profound abscopal effect was observed with tumor-localized ICB using i.t. 
administration, demonstrating the generation of an anti-tumor immune response that is 
systemically functional. It also suggests that tumor localized therapy is capable of expanding 
endogenous anti-tumor immunity, given observations of elevated TIL frequencies. Many studies 
suggest that increasing levels of CD8 TILs improve response to immunotherapy and patient 
survival (169, 173, 190). Whether they originate from the TME or elsewhere prior to migrating 
into the TME remains unclear, however, tumor specific T cells have been found in the blood post-
ICB treatment suggesting the latter (172, 191, 192). Here, we observed elevated frequencies of 
proliferating CD8 T cells in the TME, but also in the TdLN and spleen following i.t. treatment, 
suggesting that TILs may originate from multiple tissue sites. We observed stem-like CD8 TILs; 
however, the predominate phenotype of activated CD8 TILs was effector-like, which may be due 
to proliferation and differentiation of tumor resident stem-like CD8 T cells (163, 164). In line with 
this, stem-like CD8 TILs reside in APC-enriched niches that support their function, and loss or 
absence of these niches is associated with disease progression (193). In addition to the TME, we 





(10, 164) including human LNs (181). Thus, secondary lymphoid tissues are a potential source of 
tumor killing effector-like CD8 T cells. Consistent with this, accumulation of mAb within the 
spleen and LNs is associated with expansion of the effector-like cell pool within these tissues. 
Poorly immunogenic TMEs lacking APC niches or TILs may therefore not respond to systemic 
ICB therapy and may instead benefit from targeted delivery of ICB mAbs into lymphoid tissues 
where these stem-like CD8 T cells reside. Notably, T cell phenotyping performed here was not 
restricted to known antigen-specific T cell clones. Overall, our results support the conclusions that 
ICB therapy increases TIL frequencies and that, as TILs may originate outside the TME, lymphoid 
tissues represent potential tissue targets for ICB modulation.  
The effect of LN-directed mAb delivery was found to be beneficial in multiple therapeutic 
settings. In the B16F10 melanoma model, systemic i.p. administration led to minimal therapeutic 
efficacy that may be due to poor delivery and accumulation of ICB mAbs in the TME and TdLNs. 
ICB therapy directed towards TdLNs via i.l. forelimb administration greatly improved response 
rates regardless of aCTLA4 clone used, which we hypothesize is due to improved T cell activation 
and subsequent infiltration into the TME. Interestingly, dose de-escalation experiments revealed 
that ICB mAb directed to the TdLNs alone versus in combination with the TME via i.l. forelimb 
or i.t. administration, respectively, result in similar anti-tumor therapeutic effects. This is 
suggestive of the therapeutic benefits of ICB being conferred, at least partially, by activity within 
LNs, presumably at the APC:T cell synapse during the T cell priming phase. It may also be 
explained by the immune exclusion and poorly immunogenic hallmarks of the B16F10 model. In 
other words, drugging the TME does not afford therapeutic effects when anti-tumor TILs are 
locally absent. This concept is in line with previous observations in melanoma models where 
knockout of T cell PD1 expression does not improve tumor responses (167). This is further 





combination with a tumor vaccine resulted in longer survival. Vaccination alone resulted in 
dramatic expansion and infiltration of anti-tumor T cells, thus providing local TILs for potential 
ICB modulation. Therefore, addition of ICB directly into the tumor, along with a reduction of 
proliferating trTregs, resulted in an improved survival of i.t. treated mice. In line with neoadjuvant 
phenotyping results, addition of ICB therapy increased frequencies of TILs, which may be due to 
the elevated levels of proliferating T cells in lymphoid tissues. This suggests that modulation of 
ICB in the spleen or TdLN may promote and sustain tumor TIL infiltration.  
In breast tumor models, targeting mAb to (Td)LNs alone or in combination with the TME 
improved therapeutic benefits compared to systemic therapy. Drastic differences were observed in 
the E0771 model when using a trTreg depleting clone of aCTLA4 (9H10) versus a non-depleting 
clone (4F10), suggesting these tumors are highly infiltrated with suppressive Tregs and/or that 
Tregs play a dominant role in immune-regulated disease progression in these models. A LN 
drugging approach, which appears effective in eliciting robust T cell immunity, may thus need to 
be combined with other therapies to modulate such suppressive cell types to successfully combat 
breast cancer. Another consideration is tumor physiology that can vary greatly in tumor types and 
consequently affect mAb transport (34). Breast cancer models may have improved mAb access to 
the TME from the blood relative to melanoma models which may explain the i.p. efficacy 
observed. In the 4T1 model, c.l. administration improved treatment efficacy compared to systemic 
i.p. administration. This could be explained by the metastatic propensity and subsequent presence 
of tumor associated antigen in tissues beyond the TME and TdLN including nTdLNs, thereby 
explaining the beneficial effects of nTdLN targeting.  
When toxicity was explored, systemic i.p. administration led to elevated levels of ALT 
whereas locoregional delivery did not. This data may be explained by a slower, more sustained 





transport compared to a bolus delivery post i.p. administration (194). Accumulation of mAb in 
systemic tissues was proportional to administered dose. This indicates that administration routes 
that afford dose sparing, e.g. injection into locoregional tissues, have the potential to minimize off 
target toxicities. 
There is interest in locoregional delivery of mAbs as systemic administration has several 
disadvantages, including cost and compliance (195). Local immune therapy via i.t. administration 
using aCTLA4 and s.c. administration using aPD1 has been reported for a variety of cancers 
including melanoma (8, 130). However, locoregional injections hold approximately 1/10 the 
volume of systemic infusions, thus mAb solutions must be concentrated, which can lead to protein 
aggregation, and therefore compromised efficacy, increased immunogenicity, and concerns for 
pharmacokinetic profiles (194). Here, we show the LN is a tissue of interest and using route 
administration to direct ICB mAbs to TdLNs allows for efficient ICB drugging and reduced dosing 
relative to systemic administration, helping to overcome the aforementioned concerns. 
Considering i.t. injections are not always feasible due to tumor size and internal location (129), 
locoregional administration targeting the LNs and not TME directly may be advantageous as TIL 
frequencies are often low, exhausted T cells undergo epigenetic reprogramming (196) that can 
limit TIL rejuvenation potential (197, 198), and, as noted above, tumor physiology is highly 
variable which can negatively influence intratumoral mAb diffusion and lymphatic transport (89). 
TdLNs may be challenging to identify and in some cases absent due to removal during LN 
biopsy/dissection, which make this approach limited to certain indications or in neoadjuvant 
settings. Nevertheless, locoregional injection in a distant site from the tumor that drains to the same 
TdLNs may be of interest as an alternative to i.t. administration in order to broaden the number of 






In conclusion, directing ICB mAbs to (Td)LNs by locoregional administration enhanced 
anti-tumor efficacy compared to systemically administered mAb and reduced associated toxicities 
in both melanoma and breast cancers. This simple approach requires no chemical modifications to 
the ICB mAbs, only reformulation that may hold potential for clinical translation due to current 
FDA approval, interest in patient compliant administrations, and need to improve safety and 
response rates.  
3.5 Materials and Methods 
3.5.1 Experimental Design 
This study was designed to explore the mechanism and test the antitumor efficacy of ICB 
by targeting mAbs to LN tissues compared to the TME and the spleen in mouse melanoma and 
breast cancer models. We explored in what tissues immune checkpoint pathways were active and 
whether tumor localized immunotherapy led to systemic immunity by effects measured in a 
distant, untreated tumor site. We explored how ICB delivery to LNs differed from systemic 
delivery therapy in an antigen expressing cell line in combination with vaccination and endogenous 
cell lines with only ICB therapy. The goal of these experiments was to explore ways to improve 
checkpoint therapy from traditional systemic dosing. Sample sizes were chosen based on 
previously published results. For animal studies, mice were randomized prior to treatment with 
each cage having one mouse in each treatment group. Tumor growth was determined by direct 
measurement using calipers and endpoint was reached when tumor sizes reached 1.5 cm in any 
dimension. Experiments were not performed in a blinded fashion. Statistical methods are described 
in the “Statistical analysis” section.  
3.5.2 Mice and cell lines 
Cell lines were cultured in Dulbecco’s Modified Eagle Medium supplemented with 10% fetal 





mycoplasma contamination. C57Bl/6 and BalbC mice were purchased from Jackson Laboratories. 
All protocols were approved by the Institutional Animal Case and Use Committee. Tumors were 
implanted intradermally in 6-12 wk old mice and were monitored in anesthetized mice by caliper 
measurements by width, length, and depth. Mice were sacrificed when tumors led to ulceration or 
maximum tumor size of 1.5 cm in any dimension.  
3.5.3 Treatment of B16F10 melanoma bearing mice 
The backs of C57Bl6 were shaved and B16F10 cells (105) were implanted in the right dorsal area 
on day 0. After 5 (when all tumors were visible), 7, and 9 d, mice were injected with 150, 50, or 
12.5 µg of anti-mouse CTLA4 (clone: 9H10 or UC10-4F10-11, BioXCell) and/or rat anti-mouse 
PD1 (clone RMP1-14, BioXCell) intradermally into the tumor, intradermally into the forearm, or 
intraperitoneally in 30 µL saline. For distant tumor experiments, 105 B16F10 cells were injected 
intradermally on the right side of the mouse on day 0 and on the left side on day 2. On days, 5, 7, 
and 9, mice were injected with 150 µg of aCTLA4 (clone: 9H10) and aPD1 (intratumorally or 
intraperitoneally) in saline. For immune cell phenotyping, mice were sacrificed on d 12 where 
tumors, spleens, and LNs were harvested. 
3.5.4 Treatment of B16F10-OVA melanoma bearing mice 
The backs of C57Bl6 were shaved and B16F10-OVA cells (105) were implanted in the right dorsal 
area on day 0. After 4 and 10 d, CpG (3 µg) and OVA (10 µg) were administered in each limb 
using 30 µL of PBS. On day 5, 8, 11, and 14, mice received 150 µg of aCTLA4 and aPD1 i.d. into 
the tumor, i.d. into the forelimb, or i.p. in 30 µL. In mice responding to therapy, if no tumor was 
observed at day 60, mice were rechallenged with B16F10-OVA cells (105) and if no tumor was 





3.5.5 In vivo biodistribution of mAbs 
The lateral dorsal skin of C57Bl6 mice was shaved and implanted with 105 B16F10 cells on day 
0. Fluorescent labeling of aCTLA4 (9H10), aPD1 (RMP1-14), or aCD3 (KT3) was performed 
using AlexaFluor647-NHS-Ester for one hr and purified using a CL-6B sepharose column. mAb 
fractions were pooled and concentrated using a 10 kDa (Millipore) spin filter. Concentration was 
determined using a BCA assay. On day 5, mice were administered with specified dose (µg) of 
indicated aCTLA4 or aPD1 at the indicated site. For aCD3 experiments, naïve mice were used and 
injected with 6.25 µg mAb and sacrificed after 1, 5, or 24 hr when LNs were either collagenase 
treated for 30 min followed by single cell preparations (subsequently described) or immediately 
cut up and generated as a single cell suspension to prevent ex vivo T cell labeling. Fluorescent 
imaging was performed with an IVISÒ Spectrum instrument (Perkin Elmer) at the injection site 
over 24 hr and of tissues following sacrifice. Following 24 hr from Ab injection, mice were 
euthanized, and tissues collected for imaging and homogenization. Concentration in tissues was 
determined following homogenization using the injected Ab solution as a standard curve from 
naïve tissues.  
3.5.6 Tissue and single cell preparations 
Following tissue collection, tissues were processed by cutting up tissues to prevent cell surface 
receptor degradation. Single cell suspensions were generated by disrupting the organs through a 
70-mm cell strainer followed by wash steps in PBS buffer. Red blood cells were lysed with lysing 
buffer hybrid-max (Sigma) for 7 min at room temperature followed by quenching in PBS buffer. 
Cells were plated in 96-well U bottom plates where 30% of LN cells, 2 x 106 splenocytes, or 5 x 
106 tumor cells were plated for ex vivo T cell restimulation in Iscove’s modified Dulbecco’s 





LN cells, 2 x 106 splenocytes, or 5 x 106 tumor cells were plated for surface/intracellular staining 
in PBS buffer.  
3.5.7 Flow cytometry and antibodies 
Single cell suspensions from tumors, LNs, and spleens were prepared as described above. After 
washing steps, live/dead staining was performed using Zombie Aqua fixable viability kit 
(Biolegend), followed by wash steps and surface staining of molecules all from BioLegend: CD45 
(clone: 30-F11), CD3 (clone: 17A2), CD4 (GK1.5.), CD8 (clone: 53-6.7), PD1 (clone: 29F.1A12), 
FoxP3 (clone: MF-14), Tcf1 (clone: S33-966), Tim3 (clone: RMT3-23), Ki-67 (clone: 16A8) 
Granzyme B (clone: GB11). Surface staining was carried out on ice for 30 min, with tetramer 
staining done for 15 min. Intracellular staining was performed using the FoxP3 staining kit 
(eBioscience) according to the manufacturer’s instructions. All flow cytometric analyses were 
performed using a Fortessa flow cytometer (BD Biosciences) and analyzed using Flowjo software 
(Tree star). 
3.5.8 ALT assay 
For non-vaccination experiments, mice were treated with aCTLA4 and aPD1 (150 µg each) on d 
5,7, and 9 for B16F10 experiments, serum was collected on d 12. For E0771 experiments, mice 
were treated with aCTLA4 and aPD1 (100 µg each) on d 10, 14, 20 and serum collected on d 22. 
For B16F10-OVA vaccination experiments, serum was collected on d 16. ALT activity was 
measured according to manufacturer’s protocol (BioVision). 
3.5.9 Treatment of E0771 and 4T1 breast cancer bearing mice 
5 x 105 E0771 cells or 3.5 x 105 4T1 cells resuspended in 30 µL of PBS were implanted 
intradermally in the left mammary fatpad (4th) in C57Bl6 or BalbC mice respectively. For E0771 





specified area one time when tumors were ~100 mm3 or 30 µg of both aPD1 and aCTLA4 (clone: 
4F10) on d 10, 14, and 17. For 4T1 experiments, 50 µg of aPD1 and aCTLA4 (clone: 4F10) were 
administered in the specified area on d 7.  
3.5.10 PD1 staining with multiple clones 
Single-cell suspensions from tissues were prepared as described in the article. Complete media 
was spiked with PMA and ionomyocin and cells were cultured in this media for 6 hr. Following 
activation, staining was performed with a surface stain of BV785 labeled aPD1 (Biolegend, clone: 
29F.1A12) or incubated with non-fluorescent aPD1 (BioXCell, clone: RMP1-14, same clone used 
in therapeutic experiments) for 20 min on ice, followed by wash step and incubation with BV785-
aPD1 (Biolegend, clone: 29F.1A12) stain. 
3.5.11 Ex vivo T cell stimulation 
Single-cell suspensions from tissues were prepared as described in the article. Complete media 
was spiked with either ovalbumin (10 µg/mL) for CD4 T cells or SIINFEKL (1 µg/mL) for CD8 
T cells. Cells were cultured for 3 hr at 37°C followed by the addition of brefeldin A (1X: 
BioLegend) for 3 hr. Cells were harvested, stained, and analyzed by flow cytometry as described 
in the article.  
3.5.12 Treatment of E0771 and 4T1 breast cancer bearing mice 
5 x 105 E0771 cells or 3.5 x 105 4T1 cells resuspended in 30 µL of PBS were implanted 
intradermally in the left mammary fatpad (4th) in C57Bl6 or BalbC mice respectively. For E0771 
experiments, 100 µg of aPD1 or both aPD1 and aCTLA4 (clone:9H10) were administered 
intradermally in the specified area one time when tumors were ~100 mm3 (d 10 or 12) and again 4 





in the specified area on d 7 and 10. When tumors reached endpoint, mice were sacrificed with LNs 
and the spleen harvested for metastasis investigation using Image J.  
3.5.13 Treatment of B16F10 melanoma bearing mice 
The backs of C57Bl6 were shaved and B16F10 cells (5 x 105) were implanted in the right dorsal 
skin on day 0. After 5, 7, and 9 d, mice were injected with 150 µg of rat anti-mouse PD1 (clone 
RMP1-14, BioXCell) intradermally into the tumor or intraperitoneally in 30 µL saline and 
monitored for survival. 
3.5.14 Analysis of non-fluorescent aCTLA4 accumulation in dLNs 
Following 24 hours of administrations of 150 µg of aCTLA4 using i.p., c.l., and i.l. 
administrations, mice were sacrificed and draining LNs were harvested (axial and brachial). LNs 
were placed in optimal cutting temperature (OCT) compound and frozen in 2-methylbutane 
solutions using liquid nitrogen. OCT frozen LNs were sliced using a CryoStar NX70 instrument 
to 8-10 micrometers. LN sections were prepped and blocked with donkey serum, followed by an 
anti-hamster secondary staining antibody (IgG). LNs sections were then read on a Laser Scanning 
Confocal microscope (Zeiss 700) and analyzed using Zeiss Blue software.  
3.5.15 Flow cytometry antibodies 
Staining was performed as described in the article. In addition to the aforementioned antibodies, 
CXCR5 (clone: L138D7), CD39 (clone: Duha59), IFN-g (clone: XMG1.2), and TNF-a (clone: 
MP6-XT22) were used. 
3.5.16 Statistical analysis 
Statistical significance of differences between experimental groups was calculated with Prism 
software (GraphPad). All data is expressed as mean ± standard error mean except for tumor 





or two-way ANOVA followed by Tukey post-hoc test for multiple comparisons. For survival 







CHAPTER 4. ENGINEERING A DRUG ELUTING 
CHECKPOINT ANTIBODY-NANOPARTICLE CONJUGATE 
PLATFORM TO ENHANCE CANCER IMMUNOTHERAPY 
4.1 Introduction 
Cancer immunotherapy utilizes the body’s own immune system, rather than cytotoxic 
agents like chemotherapeutics, to recognize and eradicate cancers.(199) One way this is achieved 
is through activation and invigoration of T cells via immune checkpoint blockade (ICB) using 
monoclonal antibody (mAb) immunotherapies, such as anti-programmed cell death 1 (aPD1) and 
anti-cytotoxic T-lymphocyte associated protein 4 (aCTLA4).(156, 200) While ICB therapies have 
generated tremendous improvements in the survival of responsive patients, response rates of ICB 
therapies remain low and are thus combinations with other small molecule immune modulators 
that block non-redundant suppressive pathways are actively being explored to overcome ICB 
resistance.(7, 201) However, the ability to deliver small molecule therapeutics to cells of interest 
at bioactive doses to completely harness the potential of immunotherapy remains challenging as 
these drugs distribute in a non-affinity based manner and have short circulation times.(202) We 
therefore engineered an antibody-nanoparticle conjugate (ANC) platform to achieve targeted 
delivery of small molecule immune modulating drugs with ICB mAbs to immune checkpoint 
expressing cells to generate a more robust anti-tumor immune response.  
While many nanoparticle (NP) platforms have been described elsewhere, they primarily 
rely on passive accumulation within the tumor microenvironment (TME).(203) However, 
accumulation within the TME can vary dramatically and primarily relies on the enhanced 





initially proposed.(99) Furthermore, the development of targeted platforms have been engineering 
including ANCs and antibody drug conjugates (ADCs) yet have primarily focused on tumor 
targeting strategies to deliver toxic chemotherapeutic agents to eliminate cancer cells.(204, 205) 
While promising, these do require large doses to fully target and saturate tumor cells and may 
require a stimuli to release the delivered drug via pH or enzyme presence within tumor cells or 
tissue.(206) Instead, we leveraged ANCs to target T lymphocytes which release encapsulated drug 
in a sustained paracrine fashion requiring no stimuli. The NP utilized herein are composed of a 
hydrophobic poly(propylene) sulfide core with a hydrophilic polyethylene glycol (PEG) corona 
which allows for efficient encapsulation of hydrophobic small molecule drugs into the core(207) 
and surface functionalization with proteins.(208) Using this approach thus allows for improved 
drug potency as it is localized to the cell surface and requires no chemical modifications to the 
drug structure. Furthermore, rather than needing to deliver ANCs directly to the TME, ANCs may 
bind to T cells within systemic tissues trafficking into the TME which provides an additional route 
to achieve bioactive doses in the TME. 
The transforming growth factor-beta (TGFb) has garnered attention recently as it is 
commonly upregulated in tumor microenvironments and lymphoid tissues where it can promote 
suppressive milieus, in part by suppression of T cell cytotoxic function.(3, 63) Furthermore, 
heightened  TGFb signaling can reduce T cell infiltration into the TME leading to immune 
excluded tumors of which have been shown to respond poorly to ICB therapies.(209, 210) We 
hypothesized that codelivery of SB-431542, a TGFb kinase inhibitor, and ICB to tumor resident 
checkpoint expressing cells using ANCs could combat immune-excluded tumors thereby 
improving anti-tumor efficacy. In addition to ANCs enabling codelivery of TGFb inhibition and 





with target cells as immune infiltration into the TME happens continuously during tumor 
progression.  
  Adenosine signaling pathways have also emerged drug candidates to combine with ICB 
as adenosine concentrations are greatly increased within tumor tissues as cancer cells rapidly 
turnover and release intracellular adenosine triphosphate which is broken down to free adenosine 
by CD39 and CD73, surface ectonucleotidases.(76, 211) Free adenosine acts to suppress effective 
CD8 T cell priming within lymph nodes (LNs) and helps protect tumor cells via suppressed CD8 
T cell cytotoxic function.(80, 212) This has spurred the development of various adenosine 
modulation strategies including mAbs targeting CD39 and CD73 to prevent adenosine 
formation(71) along with several small molecule adenosine receptor antagonists(4) including those 
for the adenosine 2A receptor which has a high adenosine affinity.(72) We hypothesized that 
codelivery of SCH-58261 to PD1 expressing T cells would improve anti-tumor responses as these 
pathways, while non-redundant, have been shown to upregulate each other’s expression upon 
modulation of either pathway.(81, 82)  
We hypothesized that sustained delivery of small molecule immune modulators using 
ANCs directed towards checkpoint expressing immune cells would improve anti-tumor responses 
compared to non-targeted delivery. We show successful engineering of ANCs using a gentle but 
robust synthesis and conjugation schema that retains conjugated mAb binding functions that is 
versatile and applicable to multiple mAbs. Using this platform, we show ANCs can target 
checkpoint expressing cells and sustain delivery of a small molecule agent. ANCs also have a 
unique biodistribution profile that improves both mAb retention at the site of injection and 
accumulation within draining LNs. ANCs targeting results in improved colocalization with both 
circulating and LN resident T cells over short time scales that correspond to improved therapeutic 





antagonist to immune checkpoints expressed by immune cells compared to non-targeted 
formulations is substantially improved in two animal tumor models using both systemic and local 
administrations. These so-called drug eluting ICB-ANC thus demonstrate the unique benefits of 
co-delivery formulations for improving combination therapy of ICB mAb with small molecule 
immunomodulators.  
4.2 Results and Discussions 
4.2.1 Antibody-Nanoparticles Conjugates (ANCs) retain Fab binding.  
 
As Abs rely on their tertiary structure for their recognition functions, we utilized a 
previously described NP platform functionalized and bioconjugation scheme based on reacting 
thiol containing species with pyridyl disulfide (PDS) groups on the corona of polymeric NP(208) 
































Control Control NPs aCD3-ANCs Free aCD3 
Figure 22: Antibody conjugated nanoparticle (ANC) synthesis. A) Synthesis scheme B) Ratio 
of thiolated Ab to NP determine disulfide bonds as measured by released pyridyl absorbance (340 
nm). C) Size exclusion chromatography is used to purify away non-conjugated Ab. Only when 
Abs are modified with Traut’s reagent are ACNs generated. D) Dynamic light scattering plots of 
NPs and ANCs post purification. E) Representative flow cytometry plots of T cell binding using 
different formulations after incubation ex vivo with mouse splenocytes. F) Quantification of F. 






(referred to as PDS-NPs) to form ANCs (Fig. 22A). The advantage of this method is the use of 
gentle, aqueous solvents and rapid reaction times to minimize loss of mAb functions. Thiols were 
amended onto commercially purchased mAbs by treatment with 2-iminothiolane (Traut’s reagent). 
The resulting extent of thiolation was proportional to molar excess used (Fig. 23A). After cleaning, 
thiolated mAb were incubated overnight with poly(propylene sulfide) NP synthesized by emulsion 
polymerization and derivatized post synthesis with PDS (referred to as PDS-NPs). Through a 
disulfide displacement reaction monitored by absorbance at 340 nm of the displaced pyridyl group, 
the generation of ANCs could be monitored, which occurred in a manner proportional to both the 
mAb thiolation (Fig. 23B) and ratio of thiolated mAb to PDS-NP (Fig. 22B). ANC were purified 
from unreacted mAb by size exclusion chromatography (Fig. 22C) and ANC-containing fractions 
were collected and concentrated, processes that did not influence ANC hydrodynamic size (Fig. 
22D), prior to further investigations. Rhodamine labeled anti-CD3 (aCD3) to Alexa-Fluor 647 
labeled PDS-NPs yielding aCD3-ANCs that were incubated with lymphocytes engaged with T 
cells (CD3+) within murine splenocyte suspensions to similar extents (as quantified in the double 
positive gate) compared to free (non-NP conjugated, rhodamine labelled) aCD3 mAb (single 
positive for mAb) as control (Fig. 22E-F). These results demonstrate mAb functionality is 
sustained upon ANC formation.  
Figure 23: Antibody conjugated nanoparticle (ANC) synthesis measured by absorbance. 
Figure 23: Antibody conjugated nanoparticle (ANC) synthesis measured by 
absorbance. A) Excess traut’s reagent controls number of thiols on Ab surface. B) 
Thiol concentration on Ab surface determines disulfide bonds as measured by 






4.2.2 Anti-tumor efficacy of ANC-mediated ICB 
 
The ability of NP conjugation to improve mAb retention after injection, biodistribution 
analysis via IVIS imaging was performed. After i.t. injection, ANC were found to prolong mAb 
retention at the injection site over 48 h (Fig. 24A). The potential of this feature of the ANC to 
potentiate the therapeutic effects of ICB, which targets immune checkpoint molecules expressed 
by T cells (Fig. 24B) was explored. aPD1-ANCs were found to engage PD1-expression EL4 
thymoma cells (Fig. 24C). When administered i.t., aPD1-ANCs were as efficacious as free mAb, 
which both exhibited improved effects and survival benefit over systemic intraperitoneal (i.p.) 
injection free aPD1 (Fig. 24D-E). These results demonstrate that ANCs maintain the beneficial 
therapeutic effects of ICB.  
Figure 24: aPD1-ANCs have similar anti-tumor efficacy compared to free aPD1. 
aPD1 stain (BV785 labeled) 
aPD1-ANC Block (unlabeled)  













Figure 24: aPD1-ANCs have similar anti-tumor efficacy compared to free aPD1. A) Antibody 
retention using ANC or free formulation at injection site. B) Immune checkpoint expression of 
tumor resident T cells. C) aPD1-ANCs bind to EL4 cells, purple line – EL4 expression of PD1, 
blue line – aPD1-ANCs bind and prevent labeled aPD1 from labeling EL4 cells. D) B16F10 tumor 
growth using aPD1 monotherapy (non-drug loaded). E) Survival curves of D. Statistical analyses 
were done using ANOVA with Tukey’s test. Log-rank (Mantel-Cox) test for survival curves. *p < 






4.2.3 Targeting of drug eluting ANCs to immune checkpoints improves anti-tumor effects 
ANC offer multiple unique advantages to combination immunotherapies, including mAb 
multivalency, tailorable biodistribution profiles, and the capacity to co-formulate agents with 
synergistic or orthogonal bioactivities to potentiate drug effects. The potential for ANC formed 
from therapeutic mAb with amphiphilic NP to encapsulate drug to facilitate its release and effects 
in a targeted manner was explored (Fig. 25A). As proof-of-concept, amphiphilic chemotherapeutic 
paclitaxel (PTX) well established for its cytostatic activities and poorly soluble in aqueous 
solutions was encapsulated into the NP,(207) which enabled sustained release over days (Fig. 
25B). Its dose-dependent effects on EL4 cultures when incorporated into the NP were only 
modestly reduced (Fig. 25C). As aPD1-ANCs result in targeting-dependent association of NPs 
with PD1-expressing EL4 cells in vitro (Fig. 25D-E), PXL-loaded ANCs were found to induce 
concentration-dependent EL4 cell death that was enhanced by aPD1 targeting (Fig. 25F). These 
results highlight the ability of ANCs to deliver small molecule cargo in a targeted manner.  
Figure 25: ANC mediated delivery of PXL sustains drug effects to PD1 expressing target cells. 
Figure 25: ANC mediated delivery of PXL sustains drug effects to PD1 expressing 
target cells. A) Schematic demonstrating co-delivery of ICB and small molecule drug to T 
cells of interest. B) Paclitaxel release from NPs. C) Toxicity curves using paclitaxel with 
EL4 cells in vitro. D) aPD1-ANCs (fluorescently labeled NPs) facilitate NPs to bind to EL4 
cells. E) MFI quantified from D. F) Paclitaxel loaded aPD1-ANCs selectively kill PD1 
expressing cells. Statistical analyses were done using ANOVA with Tukey’s test. *p < 0.05, 
























































To assess the therapeutic potential of immunotherapeutic codelivery via drug eluting ANC, 
delivery of TGFb kinase inhibitor SB-431542 to immune checkpoint expressing T cells was 
investigated as the TGFb pathway has been previously reported to promote immune 
exclusion(209, 210) and its inhibition may help overcome the immune-excluded B16F10 tumors 
observed (Fig. 26A) following treatment with non-drug loaded aPD1-ANCs described earlier (Fig. 
24D-E). Like PXL, encapsulated SB-431542 was released from NP over 24 hours (Fig. 26B). 
When PXL-a administered i.t., targeting of SB-431542-encapsulating NP via aPD1 and aCTLA4 
(6 µg each) dramatically improved the therapeutic effects of combination therapy compared to 
non-targeted SB-431542-encapsulating NP functionalized isotype mAb when co-administered 
with aPD1 and aCTLA4-ANCs with respect to reduced tumor growth (Fig. 26C-D), resulting in 
Figure 26: Targeted TGFb  inhibition locally improves anti-tumor response. 
Figure 26: Targeted TGFb  inhibition locally improves anti-tumor response. A) T cell 
infiltration in B16F10 tumors from 2D. B) SB-431542 release from NPs. C) B16F10 tumor 
growth using aPD1, aCTLA4, and TGFb inhibitor using various formulations. D) Tumor 
volume at day 15. E) Survival curves of C. Statistical analyses were done using ANOVA 
with Tukey’s test. Log-rank (Mantel-Cox) test for survival curves. **p < 0.01, ***p < 









































































prolonged animal survival (Fig. 26E). Targeting of SB-431542 via ICB thus improves the 
combination therapeutic effects. 
 
4.2.4 Adenosine suppression is active in TNBC and antagonism restores T cell function  
 
 Adenosine is commonly upregulated in cancers and contributes to immune suppression, 
including TNBC which currently is lacking targeted therapies.(213) We thus explored the levels 
of adenosine and PD1 in the 4T1 tumor model of TNBC. Adenosine concentrations in the serum 
Figure 27: Adenosine and PD1 are upregulated in 4T1 tumor model. 
Figure 27: Adenosine and PD1 are upregulated in 4T1 tumor model. A) Adenosine 
concentrations in serum and LNs from 4T1 tumor bearing mice. B) PD1 expression in CD8, 
CD4, and NK cell populations in various tissues from 4T1 bearing mice. C) Flow cytometry 
plots for Ki-67 in ex vivo stimulated CD8 T cells using adenosine and SCH-58261. D) 
Quantified flow cytometry data of Ki-67 expression in CD8 T cells. E) Quantified flow 
cytometry data of IFNg  expression in CD8 T cells. Statistical analyses were done using 











and TdLNs of tumor bearing mice were found to be significantly increased (Fig. 27A), which we 
hypothesize is due to the high metastatic propensity of this model to infiltrate systemic tissues and 
TdLNs.(214) Within these same tissues, frequencies of PD1+ cells were also found to be high 
within CD8 and CD4 T cells and NK cells (Fig. 27B). Based off these active pathways, along with 
reports showing upregulation of A2A receptor expression in PD1 expressing T cells, we explored 
whether adenosine receptor antagonism could restore T cell activity. In line with this, CD8 T cells 
incubated with aCD3/aCD28 dynabeads in the presence of adenosine resulted in suppressed IFNg 
production and Ki-67 expression, effects reversed by co-treatment with SCH-58261 (Fig. 27C-E). 
These results highlight the adenosine and PD1 mediated suppression in the 4T1 TNBC model and 
the ability for adenosine receptor antagonism to rescue immune suppression.  
 
4.2.5 Targeting of ANCs to IC enables targeting of circulating and lymph node resident T cells  
While ANCs are able to successfully bind to T cells in vitro (Fig. 22) and sustain mAb 
retention at the site of injection (Fig. 24A), we explored whether ANCs could successfully target 
and interact with circulating and peripheral T cells in vivo. aCD3-ANC administered  i.v. resulted 
in 90% of T cells within the blood and spleen being NP-associated 1 h post treatment, in contrast 
to isotype-ANCs (<10%, Fig. 28A-B). aCD3 targeted also improved delivery to LN-, but not 
tumor-, localized T cells but to substantially lower extents (Fig. 28B). Off target uptake by B cells 
was higher for aCD3- relative to isotype-ANC (Fig. 28C).  
Unsurprising given the requirement of interstitial retention to facilitate lymphatic 
uptake,(112) accumulation of isotype mAb within the dLN was also increased with NP conjugation 
at 24 h post injection (Fig. 29A-B). Furthermore, isotype-ANC appeared to not be solely restricted 
to the LN periphery (and presumably not restricted from the LN parenchyma, Fig. 29C), the 





















ANC forms was administered i.d. and labeling of CD4 and CD8+ cells within dLN assessed 24 h 
post injection (Fig. 29D-E). Strikingly, approximately 40% of T cells labeled with aCD3-ANCs, 
levels comparable to labeling achieved using free aCD3. Correspondingly, ~40% of T cells were 
also NP+ (AlexaFluor647+), in sharp contrast to the <1% of T cells were labeled with control, 
non-targeted NPs (Fig. 29D-E), results in line with previous literature.(144) Very little association 
with off-target cells was noted, including B cells (Fig. 29F). ANC thus improves delivery to dLN 
of mAb and mAb targeting improves NP delivery to localized immune cells.  
Figure 28: aCD3-ANCs bind to T cells in vivo after i.v. administration. 
Figure 28: aCD3-ANCs bind to T cells in vivo after i.v. administration. 
AlexaFluor 647 ANCs (isotype or aPD1) were administered intravenously in 
4T1 bearing mice. One hour after administration, mice were euthanized and 
tissues processed for flow cytometry. A) Flow cytometry plots of NP binding to 
CD4/CD8 T cells. B) NP binding from A quantified. C) NP binding to B cells. 
Statistical analyses were done using ANOVA with Tukey’s test. **p < 0.01, 













4.2.6 IC targeted antagonism of adenosine reduces breast cancer growth and metastasis 
 
 The potential for aPD1 targeting of ANCs co-delivering SCH-58261 to PD1 expressing 
cells to augment anti-tumor immune response compared to non-targeted therapy was next 
explored. NP encapsulation that improved SCH-58261 solubility (Fig. 30A) resulted in 50% of 
drug to be released within 9 h (Fig. 30B). When systemically administered, i.v. administration of 
Figure 29: i.d. administration of ANCs improves  mAb LN accumulation and access. Figure 29: i.d. administration of ANCs improves  mAb LN accumulation and access. A) 
Isotype Ab accumulation in dLNs using various formulations. B) Quantification of isotype Ab 
accumulation in LNs via homogenization. C) Confocal microscopy of whole LNs using isotype 
Ab. D) Flow cytometry plots of aCD3 and NP accumulation in LNs of CD4+ & CD8+ T cells. E) 
Quantified flow cytometry data of D. F) Flow cytometry of aCD3 and NPs in B cell compartment. 
Statistical analyses were done using ANOVA with Tukey’s test. *p < 0.05, **p < 0.01, ***p < 
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60 µg of aPD1, either in the free or ANC formulation along with 2 µg of encapsulated SCH-58261 
in isotype- or aPD1-ANCs resulted in reduced 4T1 tumor growth, that was improved by drug-















Figure  Adenosi e a tagonist loaded aPD1-ANCs improve anti-tum r th rapy compared 
to non-targeted ANCs. A) AA is soluble in aqueous solvents when encapsulated in NPs. B) AA 
release profile from NPs using dialysis filters. C-H) Systemic administration of drug formulations. 
C) 4T1 tumor growth using Isotype- and aPD1-ANCs loaded with AA over first 35 days. D) Tumor 
volume at day 35. E) Flow cytometry plots of LNs. F) Quantified levels of lymphocytes cells in 
LNs on day 35. Dotted line represents % lymphocytes in non-tumor bearing mice LN. G) Spleen 
area size of 4T1 treated mice. Dotted line represents spleen area in non-tumor bearing mice, 
statistics below dotted line compared to non-tumor bearing mouse spleen size. H) Survival of 4T1 
animals. I-K) i.d. administration of drug formulations. I) Injection location for i.d. administration. 
H) Tumor growth curves. I) Survival curves H. Statistical analyses were done using ANOVA with 
Tukey’s test. Log-rank (Mantel-Cox) test for survival curves. *p < 0.05, **p < 0.01, ****p < 






eluting ANC targeting (Fig. 30C). As with primary tumors 20 d after the last treatment on day 35 
post tumor implantation that demonstrated reduced growth resulting from aPD1-ANC 
encapsulating SCH-58261 (Fig. 30D), metastatic tumor burden in LNs was reduced, as indicated 
by reduced immune cell frequencies relative to non-TdLNs and LNs from non-tumor bearing mice 
(Fig. 30E-F). Furthermore, spleen size, which has previously been correlated with metastatic 
disease burden(214), was found to be reduced in animals treated with aPD1-ANC encapsulating 
SCH-58261 and comparable to the sizes of non-tumor bearing mice (Fig. 30G). Survival of a 
separate mouse cohort treated using the same schedule demonstrated improved animal survival by 
aPD1 targeting of NP-encapsulated SCH-58261 (Fig. 30H). Similarly, when administered i.d. into 
the forelimb ipsilateral to the tumor (thus resulting in drainage to LNs co-draining the tumor, Fig. 
8I) and with the same treatment schedule described above, SCH58261 loaded aPD1-ANCs reduced 
tumor growth and prolonged mouse survival compared to non-targeted SCH-58261 loaded 
isotype-ANCs (Fig. 30J-K). These results highlight the ability of drug eluting targeted ANC to 
improve combination immunotherapy for TNBC.  
4.3 Conclusions 
 An ANC platform capable of delivering small molecule therapeutics in a targeted fashion 
to immune checkpoint expressing cells was developed as a versatile system to augment targeted 
delivery and sustain drug synergies to improve combination cancer immunotherapies. Using this 
platform, delivery of three unique small molecule compounds was improved; model 
chemotherapeutic drug PXL, a TGFb kinase inhibitor, and an adenosine receptor antagonist. 
Interestingly each of these three drugs works in different cellular locations; the nucleus, cytoplasm, 
and extracellular surface, respectively, suggesting the capacity of NP-released small molecule to 
drug cells within multiple intracellular compartments. To this end, we show released drug retains 





the cargo, a major barrier that can affect drug activity in other platforms. Furthermore, the mAb 
conjugation synthesis can be applied to multiple mAb while retaining binding activity as the 
reaction conditions are mild (require no heating, organic solvents, etc). Due to their low levels of 
phagocytosis and pinocytosis, T cells represent a challenging target to drug via passive targeting, 
yet are immensely important for generating robust anti-cancer immune responses.(215) Our results 
demonstrate the ability to target T cells both in vitro and in vivo using targeting mAbs is not 
impaired by incorporation into ANCs and dramatically improves co-association of ANCs with T 
cells relative to isotype-ANCs. Furthermore, ANC formulation did not diminish effects of ICB. 
When leveraging the NP as a drug reservoir, anti-tumor responses induced by the synergies of ICB 
with immune modulators were substantial. As immune suppression and exclusion has emerged as 
a multi-pathway process, thus requiring multiple modes of modulation to fully restore cytotoxic 
function, the potential of enabling codelivery of multiple immunotherapies and immune synergies 
is enormous.(216) Conventional combination therapies consists of co-administered agents but is 
unlikely to lead to concurrent delivery to and thus modulation to the same cell target, thereby 
diminishing effects. Considering the emerging interest in combining ICB therapies with other 
small molecule modulators including those targeting the TGFb and adenosine pathways, these 
results highlight the potential for co-delivery approaches, such as the drug eluting immune 
checkpoint inhibitor ANC approach described herein, to substantially improve therapeutic 
efficacy. 
4.4 Materials and Methods 
4.4.1 Synthesis of PDS-NPs. Poly(propylene sulfide) NPs are synthesized according to previous 
literature. Briefly, 500 mg of –COOH Pluronic F127 is dissolved in 10 mL of DI water for 30 min 
under argon, followed by addition of 400 µL of propylene sulfide for 15 min. Initiator(143) is 





15 min. 1,8-Diazabicyclo[5.4.0]undec-7-ene is subsequently added and stirred overnight followed 
by reaction exposure to oxygen (uncapping) for 2 h to mediate crosslinking of the NP core. NPs 
are then dialyzed against DI water using a 100,000 Da MW cutoff cellulose membrane dialysis 
tubing (SpectrumLabs). Following dialysis, core thiols are capped using either N-ethylmaleimide 
or Alexa Fluor 647-maleimide, followed by N-ethylmaleimide in 1X PBS overnight. NPs are 
functionalized with pyridyl disulfide (PDS) on the carboxy Pluronic using EDC/NHS crosslinking 
for 24 h followed by dialysis against DI water for 3 d, yielding PDS-NPs. 
4.4.2 Antibody thiolation. mAb were thiolated by reacting with 2-iminothiolane (Traut’s reagent) 
in 1X PBS at room temperature for 60 min with stirring. Thiolated mAb was subsequently purified 
using a 7 kDa MW cutoff zeba filter according to manufacturer’s instructions. The number of 
thiols per IgG molecule was determined by Ellman’s assay using a thiomalic acid standard curve. 
Thiolated mAb was immediately used for NP conjugation and characterization.  
4.4.3 ANC synthesis and purification. Thiolated-mAb was mixed with PDS-NPs and reacted 
overnight at RT while stirring. Following reaction, ANCs were purified from unreacted mAb using 
size exclusion chromatography using a Sepharose 4B resin. ANC-containing fractions identified 
using fluorescamine and concentrated using a 4 mL 30 kDa MW cutoff spin filters and stored until 
use at 4° C. Final mAb concentrations in ANC suspensions were determined using the 
bicinchoninic acid protein assay kit (ThermoFisher). Following initial synthesis parameters, we 
synthesized subsequent ANCs using a 40 fold molar excess of trauts which equated to a 6-8 molar 
thiol concentration per antibody and 0.2-0.6 mgs of antibody to mgs of NP pending the application.  
4.4.4 ANC binding to target ligand. Anti-CD3 (clone:KT3, BioXcell) or aPD1 (clone:29F.1A12, 
BioXcell) mAb were conjugated to AlexaFluor 647 labelled PDS-NPs. ANCs were incubated with 
the lymphocytes or EL4 cell suspensions in 96 well plates for 15 min on ice and then stained for 





cells were incubated with stock, non-fluorescent aPD1 mAb for 15 min on ice, followed by 
washing step in phosphate buffered saline (PBS), followed by 15 min incubation with aPD1 mAb 
or aPD1-ANCs, followed by processing for conventional surface staining (described below) for 
flow cytometry analysis. 
4.4.5 Tissue and single cell preparations. Following tissue collection, tissues were processed by 
cutting rather than enzymatic digestion to prevent cell surface receptor degradation. Single cell 
suspensions were generated by disrupting organs through a 70-mm cell strainer followed by wash 
steps in PBS. Red blood cells were lysed with lysing buffer hybrid-max (Sigma) for 7 min at room 
temperature followed by quenching in PBS. Cells were plated in 96-well U bottom plates for 
surface/intracellular staining in PBS.  
4.4.6 Flow cytometry and antibodies. Single cell suspensions from tumors, LNs, and spleens were 
prepared as described above. After washing, live/dead staining was performed using Zombie Aqua 
fixable viability kit (Biolegend), followed by wash steps and surface staining using mAb (all from 
Biolegend): CD45 (clone: 30-F11), CD3 (clone: 17A2), CD4 (GK1.5.), CD8 (clone: 53-6.7), 
NK1.1 (PK136), B220 (RA3-6B2), CD19 (6D5), IFN-g (clone: XMG1.2), PD1 (clone: 29F.1A12 
or RMP1-14). Surface staining was carried out on ice for 30 min. All flow cytometric analyses 
were performed using a Fortessa flow cytometer (BD Biosciences) and analyzed using Flowjo 
software (Tree star). 
4.4.7 Small molecule encapsulation and drug release profiles. To encapsulate small molecule 
drugs, lyophilized drug was reconstituted at 10 mg/ml in DMSO. Stock drug was subsequently 
dispersed into 30 µL ANC suspension or PBS by simple pipette mixing. Drug loaded ANCs 
suspensions or drug solutions were then loaded into dialysis cups (100 kDa MWCO, 
ThermoFisher) and dialyzed against PBS with constant stirring. Dialysate were periodically 





4.4.8 Animals and cell lines. Cell lines were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin/amphotericin B  referred to as complete media and periodically checked 
for mycoplasma contamination. C57Bl/6 and BalbC mice were purchased from Jackson 
Laboratories. All protocols were approved by the Institutional Animal Case and Use Committee. 
Tumors were implanted intradermally in 6-12 wk old mice and were monitored in anesthetized 
mice by caliper measurements by width, length, and depth. Mice were sacrificed when tumors led 
to ulceration or maximum tumor size of 1.5 cm in any dimension.  
4.4.9 In vitro cytotoxic effects of PTX. EL4 cells were cultured and plated in 96-well plates at a 
density of 105 cells per well in 198 µL of complete media. 2 µL of sample (vehicle, PTX, ANC 
formulation) was added to each well and allowed to incubate for 4 d. Cells were then stained for 
flow cytometry with LiveDead marker to determine IC50 curves. To investigate targeted ANC 
potential, cells were plated, and sample added as mentioned, but following a 25 min incubation of 
sample with cells on ice in 1% BSA in PBS, cells were then pelleted and washed twice with 
complete media before incubating for 2 d followed by flow cytometry staining. 
4.4.10 In vivo mAb biodistribution. Fluorescent labeling of isotype or aCD3 (KT3, BioXCell) mAb 
was done using AlexaFluor700-NHS-Ester for 1 h following by purification using a Sepharose 
CL-6B column with fluorescent mAb fractions pooled and concentrated using a 10 kDa (Millipore) 
spin filter. mAb concentrations were determined using a BCA assay. Fluorescent NPs (AlexaFluor 
647) were synthesized as previously mentioned. The lateral dorsal skin of C57Bl6 mice was shaved 
and mAb or ANCs were administered using the specified administration route at the indicated site. 
For retention studies, fluorescent imaging was performed with an IVISÒ Spectrum instrument 
(Perkin Elmer) at the injection site over 3 d and of tissues following sacrifice. Following 24 h from 





Concentration in tissues were determined following homogenization using the injected mAb or 
ANC solutions as a standard curve from naïve tissues.  For aCD3 experiments, naïve mice were 
used and injected with either 40 or 6.25 µg of mAb for i.v. and i.d. administration respectively. 
For i.v. biodistribution, mice were euthanized after 1 h with tissues collected and processed for 
flow cytometry. For aCD3 labeling of T cells within LNs following i.d. administration, mice were 
euthanized after 24 h after injection and resected LNs were either collagenase treated for 30 min 
or immediately digested with scissors to prevent ex vivo T cell labeling followed by processing 
into single cell suspensions (previously described).  
4.4.11 B16F10 melanoma bearing mice treatments. The dorsal skin of C57Bl6 mice was shaved 
and B16F10 cells (105) implanted in the right lateral dorsal skin on day 0. After 5 (when all tumors 
were visible), 7, and 9 d, mice were injected i.d. with 10 µg of anti-mouse CTLA4- (clone:UC10-
4F10-11, BioXCell) and rat anti-mouse PD1-ANCs (clone: 29F.1A12, BioXCell) or Armenian 
hamster IgG- (BioXcell) and rat isotype control-ANCs (clone: 2A3) in 30 µL saline. 5 µg of 
SB431542 (Sigma) was encapsulated in aforementioned ANCs prior to injection. Mice were 
monitored every other day for survival studies. For immunofluorescence studies, mice were 
euthanized at endpoint and tumors were harvested. Tumors were placed in optimal cutting 
temperature (OCT) compound and frozen in 2-methylbutane solutions using liquid nitrogen. OCT 
frozen tumors were sliced using a CryoStar NX70 instrument to 8-10 um. Tumor sections were 
blocked with donkey serum, followed by an anti-CD3 (FITC) primary staining antibody (IgG). 
Tumors sections were then read on a Laser Scanning Confocal microscope (Zeiss 700) and 
analyzed using Zeiss Blue software.  
4.4.12 Quantification of adenosine and PD1 expression in 4T1 model. 3.5 x 105 4T1 cells 
resuspended in 30 µL of PBS were implanted i.d. in the left mammary fatpad (4th) in BalbC mice. 





disrupted in a 96 well round bottom plate for ELISA assays. Following disruption, debris was 
pelleted, and supernatants collected, and adenosine levels measured by ELISA (Abcam) according 
to the on manufacturer’s protocol. To determine PD1 expression, on day 15 post tumor 
implantation, tissues were collected and processed for flow cytometry. 
4.4.13 4T1 breast tumor bearing mouse treatments. 3.5 x 105 4T1 cells resuspended in 30 µL of 
PBS were implanted i.d. in the left mammary fatpad (4th) in BalbC mice and 60 µg of aPD1 mAb 
with 2 µg of SCH58261 (Sigma) was administered in the aforementioned areas on days 6, 9, 12, 
and 15. Tumors were monitored every 2-3 d until endpoint for survival analysis. Analysis of 
metastatic disease, mice were sacrificed day 35 mice and the spleen and LNs collected. TdLNs 
and nTdLNs were harvested and prepared for flow cytometry analysis as described above and the 
spleen areas were analyzed by ImageJ. 
4.4.14 Statistical analysis. Statistical significance of differences between experimental groups was 
calculated with Prism software (GraphPad). All data is expressed as mean ± standard error mean 
except for tumor growth. ****p<0.0001, ***p<0.001, **p<0.01, and *p<0.05 by unpaired two-
tailed t-tests or one- or two-way ANOVA followed by Tukey post-hoc test for multiple 









CHAPTER 5. CONCLUDING REMARKS AND FUTURE 
DIRECTIONS 
5.1 Conclusions 
 ICB immunotherapy has rapidly emerged as the most promising form of cancer therapy as 
it offers robust responses and complete cures in some patients. However, these therapies are far 
from ideal with three main challenges remaining; 1) low response rates, 10-50% (6), 2) high rates 
of iRAEs (7), and 3) partial responses, but high levels of relapse over time (6). While current 
research has made great strides of overcoming these barriers through better understandings of how 
ICB therapies work and by combination with multiple therapies, the aspect of drug delivery is a 
critical barrier that may help overcome these challenges. First, mAb therapies are primarily 
administered systemically (i.v./i.p.) which results in poor TME accumulation (~1% of 
administered dose), or the canonical site of interest, thus requiring high doses to obtain a 
concentration above the therapeutic threshold in these tissues which contribute to iRAEs. Second, 
many immunotherapies are now combined with one another (e.g. aCTLA4+ aPD1) including 
combination therapies consisting of mAbs and small molecule inhibitors to simultaneously block 
independent pathways to prevent relapse. While this has improved efficacy in some patients, the 
responses are still variable and require further research (1, 3, 4, 71).  
 Given the unique characteristics of mAb therapies including large molecular size compared 
to tradition small molecule drugs (150 vs 1 kDa) as well as their affinity towards cognate ligand, 
we have harnessed these salient features to drug an alternative tissue from the TME, specifically 
the TdLNs, and have designed a biomaterial to codeliver both mAbs and small molecule drugs 
over a sustained period to T cells. In the first aim, we explored how drugging LNs which are home 
to high concentrations of T cells affects anti-tumor efficacy utilizing different administration 





we show that mAbs efficiently drain to dLNs and can access T cells within these LNs. This led to 
improved anti-tumor responses compared to traditional systemic administrations and allowed for 
reduced dosing while maintaining anti-tumor responses. In the second aim, we engineered an ANC 
to improve codelivery of multiple therapeutics to the same cell of interest to block non-redundant 
suppressive pathways, specifically immune checkpoints and TGFb or adenosine. Using the mAb 
as both a drug and targeting agent, we demonstrate both improved delivery and sustained delivery 
of small molecule drugs to cells of interest. We applied this delivery system to a variety of 
therapeutics including aPD1, aCTLA4, a TGFb inhibitor, and an adenosine receptor antagonist 
highlighting the versatility of this platform and showed improved anti-tumor responses against 
melanoma and breast cancers. 
 
5.2 Contributions to the field 
 The overall impact of this work was to explore new ways to improve cancer 
immunotherapies, specifically by focusing on drug delivery to T cells, the cells of interest for many 
drugs. While research in the immunotherapy field has advanced tremendously in the last two 
decades, it has primarily focused on discovering new druggable pathways and/or modulating 
multiple therapies concurrently via combination therapy. However, drug efficacy is partially due 
to drug reaching its target site of interest at the bioactive dose where it can then mediate its effect. 
The main contributions of this work are 1) we have identified the TdLN as a critical tissue in 
mediating the efficacy of ICB therapies and it is efficiently druggable by cutaneous administration, 
and 2) using an ANC platform, we can achieve sustained codelivery of multiple therapies to the 
same cell of interest which is required with certain combination therapies to generate an anti-tumor 
response.  





 Chapter 3 of this work described an approach to drug LNs and thus block immune 
checkpoint pathways by simply modifying the route of administration leading to improved anti-
tumor efficacy. This work helps advance the understandings of mAb biodistribution as well as the 
immunological roles of checkpoint pathways in lymphoid tissues or the priming phase. By 
drugging LNs using cutaneous administration routes, we show mAb has access to deeper areas of 
the LN, a process thought to not occur due to the size restrictions and cell barriers protecting the 
deeper T cell zones of the LN. Using various administration routes, we then demonstrate that 
TdLNs, which are bathed in tumor associated antigen (207), are critical tissues to augment ICB 
efficacy as LNs are sites of high concentrations and robust T cell proliferation (178). Additionally, 
we show that the high LN accumulation of mAb in dLNs allows for significant reductions in 
administered dose which may help reduce iRAEs. Due to the simplicity of this approach, combined 
with extensive research into mAb formulations for subcutaneous administration, this work 
provides valuable information to clinicians for local administration sites and alternatives to 
conventional i.v. administration in patients not responding to ICB therapies.  
5.2.2 ICB-ANCs for targeted and sustained small molecule drug delivery to IC expressing cells 
Chapter 4 of this work explored the design of an ANC platform to augment delivery of 
small molecule drugs to PD1 and CTLA4 expressing cells. Our system is unique as it is polymer 
based thus 1) allowing small molecule drug to be encapsulated, rather than chemically conjugated 
thereby retaining the small molecule structure and thus function and 2) allowing drug to release 
over time with no stimuli required like many other ANC or ADC platforms. This is particularly 
attractive for drugging T cells as they reside in many different microenvironments where stimuli 
including pH and enzymes vary thus complicating a stimuli release mechanism. While other ANC 
platforms have been engineered, they have primarily been focused on improving small molecule 





the best of our knowledge, is the first ANC platform to drug a T cell surface receptor with a small 
molecule immune modulator. Of the ANC platforms tailored for immune cell targeting, they have 
focused on drugging intracellular pathways as these drug carriers must be degraded in order to 
release encapsulated cargo generally intracellularly thereby preventing modulation of surface. In 
addition, this work demonstrates that codelivery of immunotherapies to the same cell of interest 
can generate or improve existing anti-cancer immune responses thus elucidating a necessary 
criterion for emerging drug delivery systems.  
5.3 Future Directions 
The future directions of my work should seek to further the applicability and translatability 
made in this thesis on modifying route of administration and co-delivery of immune modulators 
to immune cells. Regarding the aim 1 on route of administration, I would like to see this approach 
applied to other mAb therapies as the biologics field is rapidly emerging as the most popular and 
efficacious treatment approach in a plethora of disease indications not limited to oncology or ICB 
therapeutics. These mAb therapies could be applied to other ICB mAbs as many immune 
checkpoint pathways work at the priming phase within LNs or they could be applied to tumor 
targeting mAbs used to recognize and eliminate LN-resident tumors. Furthermore, non-therapeutic 
applications using this approach could be used to explore basic science questions regarding the 
adaptive or innate immune response in LNs as various mAbs can be used as ligand traps to reduce 
cytokine or other protein concentrations in LNs or can be used as depleting clones to probe 
questions about each cell compartments role in immunity. Furthermore, considering this approach 
is using FDA approved targets, developing clinically translatable formulations is a great interest I 
have as local administrations of mAbs can be challenging due to injection volume constraints and 
repeated injections in the same location. The development of a sustained mAb formulation (e.g. 





for patient compliance. In respect to aim 2, I would like to see future projects aimed at expanding 
both the immunotherapies delivered and tissues targeted with ANCs. The ANC platform can be 
applied to virtually any mAb due to the mild reaction conditions and amine/thiol conjugation 
chemistry. Furthermore, the hydrophobic NP core allows for a diversity of small molecule 
modulators to be encapsulated and delivered with this platform enabling a plethora of different 
combination strategies. By using existing and novel combinations of mAbs and small molecule 
drugs for codelivery to cells of interest, new insights on immunotherapies and improvements in 
anti-tumor responses may result that were not observed in the past lacking codelivery approaches. 
Furthermore, drugging LNs with this ANC platform has the potential to create a drug depot in 
dLNs allowing for new therapeutic interventions with less injections. Projects such as these could 
provide insight and further our understandings of mAb therapies, the role of LNs in immunological 
pathways, and help contribute towards therapeutic interventions in the cancer immunotherapy 
field. 
5.3.1 Extending LN drugging to other mAb therapies and sustained release formulations 
Future work for this approach should aim at exploring the administration of other ICB 
mAbs such as those targeting PD-L1, T cell immunoreceptor with Ig and ITIM domains (TIGIT), 
T-cell immunoglobulin and mucin-domain containing-3 (Tim3), and others involved in T cell 
activation. All of these mAbs are currently FDA approved or are in clinical trials and have 
expression on APCs/T cells which can be found in LNs, yet these therapies have variable response 
rates motivating alternative strategies to improve efficacies. From my work and others showing 
LN accumulation of mAbs is based on molecular size, therapeutic experiments should be designed, 
and anti-tumor responses measured. In addition to the LN being home to immune cells, certain 
cancers metastasize leading to LN resident tumors. Thus, these diseased tissues are prime targets 





antigens such as HER2 could be viable options using cutaneous administration to drug LN resident 
tumors and eradicate them circumventing the need for LN resections.   
Drugging LNs with mAbs outside of ligand blocking is also a potential direction, 
specifically ligand traps. Inhibiting TGFb within T cells is one way to block the suppressive 
functions, however, mAbs have been developed to sequester and prevent TGFb from exerting its 
function. Literature suggests TGFb is upregulated in TdLNs which can lead to immune 
suppression and metastatic invasion therefore reducing the concentration of TGFb here represents 
an interesting approach. Related to this, LN drugging with mAbs could be used to explore basic 
science questions as sequestering various cytokines or chemokines with ligand traps or depleting 
certain cells types in dLNs may help determine the role of these proteins/cells in different contexts 
helping to further our understandings of immunological mechanisms. 
In addition to expanding the mAb therapies, the development of a sustained release 
formulation at the injection site to prolong mAb lymphatic drainage has promising upsides. One 
of the main reasons local administrations have been developed is due to patient compliance as it 
is a much quicker administration compared to i.v. administration in terms of injection time. To 
advance this convenience, developing a system that requires one injection in the skin vs multiple 
injections may further improve patient compliance. We have done preliminary work showing 
continually drugging the dLN over several days using a hydrogel system improves anti-tumor 
immunity. This work needs to be further developed in larger animal studies and multiple tumor 
models but holds potential for translation into the clinic.  
5.3.2 Determining ANC biodistribution further and expanding applications  
 Future work for the ANC system should aim at expanding the biodistribution 
characterization as this has important implications for toxicity, efficacy, and sustained drugging 





exploring the circulation time along with tissue accumulation within the TME and LNs would be 
of great interest to determine whether affinity based ANCs show differences in these tissue targets. 
Additionally, using checkpoint targeted ANCs and exploring whether ANCs interact preferentially 
with different cell types would be of interest, i.e. would ANCs primarily accumulate with Tregs 
as they express higher levels of checkpoint receptors comparted to CD8 or Natural Killer cells. As 
eluded to earlier, T cells exert low levels of phagocytosis and pinocytosis suggesting ANCs would 
stay bound to the surface of these cells. However, directly exploring this and determining how 
long ANCs stay bound to their target T cells would be intriguing and important for sustained 
drugging applications.  
Additionally, future work for the ANC system should aim at expanding the codelivery of 
various immunotherapeutics. Due to the ease of conjugation, multiple mAbs could be conjugated 
to the same NP to block different proteins simultaneously while encapsulation of multiple small 
molecule modulators within the same NP will allow for codelivery of two classes of drugs (mAbs 
and small molecules), but also modulation of two plus pathways. We have previously shown that 
the NPs can encapsulate a diversity of small molecules separately which should be extended to the 
same NP. By expanding on the original ANC platform to deliver multiple small molecule drugs, a 
feature challenging to achieve with ADCs due to the drug loading constraint per mAb, dozens of 
pathways could theoretically by modulated within a single cell. Alternatively, using this system to 
drug LNs is another area of interest where mAbs with affinities to LN ECM proteins could be 
conjugated to ANCs to prolong retention in the LNs compared to non-targeted ANCs. Combined 
with the unique ability of ANCs to enable sustained small molecule drugging due to the 
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